<html lang="en" class="pb-page js" data-request-id="94d6a8d8a645f2b4-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6a8d8a645f2b4-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/pKMzByynhA0ohscYjTP6Ig1g8lmFllqJeHpkwVRZeHNb70da3UJHHoAaTH9DLzJafQjlPgnnwQTbXlDlqA_keQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6a8d8a645f2b4-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.26100233214182955"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Hematology/Oncology|Cardiology|Genetics|Pediatrics">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Anticoagulation/Thromboembolism (Cardiology)|Genetics General|Coagulation|Pediatrics General"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2104205","title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","category":"Research","type":"Original Article","topics":"Anticoagulation/Thromboembolism (Cardiology)|Genetics General|Coagulation|Pediatrics General","specialties":"Hematology/Oncology|Cardiology|Genetics|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-11-18T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology|Cardiology|Genetics|Pediatrics\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Anticoagulation/Thromboembolism (Cardiology)|Genetics General|Coagulation|Pediatrics General\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2104205","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","doi":"10.1056/NEJMdo006248","issueDate":"2021-11-18T00:00Z","age":"6Months-1990","isFree":"n","topics":"Genetics General|Anticoagulation/Thromboembolism (Cardiology)|Coagulation|Pediatrics General","viewType":"Full","specialties":"Hematology/Oncology|Cardiology|Genetics|Pediatrics"},{"type":"Quick Take","title":"Factor VIII Expression after Gene Therapy for Hemophilia A","doi":"10.1056/NEJMdo006247","issueDate":"2021-11-18T00:00Z","age":"6Months-1990","isFree":"n","topics":"Genetics General|Anticoagulation/Thromboembolism (Cardiology)|Coagulation|Pediatrics General","viewType":"Full","specialties":"Hematology/Oncology|Cardiology|Genetics|Pediatrics"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6a8d8a645f2b4-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A"><meta name="dc.Creator" content="Lindsey A. George"><meta name="dc.Creator" content="Paul E. Monahan"><meta name="dc.Creator" content="M. Elaine Eyster"><meta name="dc.Creator" content="Spencer K. Sullivan"><meta name="dc.Creator" content="Margaret V. Ragni"><meta name="dc.Creator" content="Stacy E. Croteau"><meta name="dc.Creator" content="John E.J. Rasko"><meta name="dc.Creator" content="Michael Recht"><meta name="dc.Creator" content="Benjamin J. Samelson-Jones"><meta name="dc.Creator" content="Amy MacDougall"><meta name="dc.Creator" content="Kristen Jaworski"><meta name="dc.Creator" content="Robert Noble"><meta name="dc.Creator" content="Marla Curran"><meta name="dc.Creator" content="Klaudia Kuranda"><meta name="dc.Creator" content="Federico Mingozzi"><meta name="dc.Creator" content="Tiffany Chang"><meta name="dc.Creator" content="Kathleen Z. Reape"><meta name="dc.Creator" content="Xavier M. Anguela"><meta name="dc.Creator" content="Katherine A. High"><meta name="dc.Description" content="The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ..."><meta name="Description" content="The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-11-18"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2104205"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202111183852108"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2104205"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2104205">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2104205">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2104205">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM">
        <meta property="og:title" content="Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2104205">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/c0d52942-def0-41fa-9959-9cbaa81257e1/nejmoa2104205_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/c0d52942-def0-41fa-9959-9cbaa81257e1/nejmoa2104205_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The goal of gene therapy for patients with hemophilia A is to safely impart long-term
stable factor VIII expression that predictably ameliorates bleeding with the use of
the lowest possible vector ...">
        <meta name="twitter:description" content="The goal of gene therapy for patients with hemophilia A is to safely impart long-term
stable factor VIII expression that predictably ameliorates bleeding with the use of
the lowest possible vector ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2104205">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2104205">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2104205;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2021.385.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2104205" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2104205" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2104205" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2104205" class="inputDoi"><input type="hidden" value="L.A. George and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:1961-1973" class="inputCitation"><input type="hidden" value="11-17-2021" class="inputEPubDate"><input type="hidden" value="November 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6a8d8a645f2b4-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Lindsey A.</span> <span property="familyName">George</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Paul E.</span> <span property="familyName">Monahan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">M. Elaine</span> <span property="familyName">Eyster</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Spencer K.</span> <span property="familyName">Sullivan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Margaret V.</span> <span property="familyName">Ragni</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stacy E.</span> <span property="familyName">Croteau</span>, <span property="honorificSuffix">M.D., M.M.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">John E.J.</span> <span property="familyName">Rasko</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+11</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael</span> <span property="familyName">Recht</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Benjamin J.</span> <span property="familyName">Samelson-Jones</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amy</span> <span property="familyName">MacDougall</span>, <span property="honorificSuffix">B.S.N.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kristen</span> <span property="familyName">Jaworski</span>, <span property="honorificSuffix">M.S.N., F.N.P.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Noble</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marla</span> <span property="familyName">Curran</span>, <span property="honorificSuffix">Dr.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Klaudia</span> <span property="familyName">Kuranda</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Federico</span> <span property="familyName">Mingozzi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tiffany</span> <span property="familyName">Chang</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kathleen Z.</span> <span property="familyName">Reape</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xavier M.</span> <span property="familyName">Anguela</span>, <span property="honorificSuffix">Ph.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Katherine A.</span> <span property="familyName">High</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-11</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">November 17, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">1961</span>-<span property="pageEnd">1973</span></div><div class="doi">DOI: 10.1056/NEJMoa2104205</div><div class="core-enumeration"><a href="/toc/nejm/385/21"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">21</span></span></a></div><div><a href="#tab-information">Copyright Â© 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DLindsey%2BA.%2BGeorge%252C%2BPaul%2BE.%2BMonahan%252C%2BM.%2BElaine%2BEyster%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D21%26contentID%3D10.1056%252FNEJMoa2104205%26title%3DMultiyear%2BFactor%2BVIII%2BExpression%2Bafter%2BAAV%2BGene%2BTransfer%2Bfor%2BHemophilia%2BA%26publicationDate%3D11%252F18%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2104205" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DLindsey%2BA.%2BGeorge%252C%2BPaul%2BE.%2BMonahan%252C%2BM.%2BElaine%2BEyster%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D21%26contentID%3D10.1056%252FNEJMoa2104205%26title%3DMultiyear%2BFactor%2BVIII%2BExpression%2Bafter%2BAAV%2BGene%2BTransfer%2Bfor%2BHemophilia%2BA%26publicationDate%3D11%252F18%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/dad36d0d-e485-4609-8516-ea2beffa9359/nejmoa2104205.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2104205.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2104205" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2104205" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2104205.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this phase 1â2 trial, we infused an investigational adeno-associated viral (AAV) vector (SPK-8011) for hepatocyte expression of factor VIII in 18 men with hemophilia A. Four dose cohorts were enrolled; the lowest-dose cohort received a dose of 5Ã10<sup>11</sup> vector genomes (vg) per kilogram of body weight, and the highest-dose cohort received 2Ã10<sup>12</sup> vg per kilogram. Some participants received glucocorticoids within 52 weeks after vector administration either to prevent or to treat a presumed AAV capsid immune response. Trial objectives included evaluation of the safety and preliminary efficacy of SPK-8011 and of the expression and durability of factor VIII.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f0.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/c0d52942-def0-41fa-9959-9cbaa81257e1/assets/images/large/nejmoa2104205_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">The median safety observation period was 36.6 months (range, 5.5 to 50.3). A total of 33 treatment-related adverse events occurred in 8 participants; 17 events were vector-related, including 1 serious adverse event, and 16 were glucocorticoid-related. Two participants lost all factor VIII expression because of an antiâAAV capsid cellular immune response that was not sensitive to immune suppression. In the remaining 16 participants, factor VIII expression was maintained; 12 of these participants were followed for more than 2 years, and a one-stage factor VIII assay showed no apparent decrease in factor VIII activity over time (mean [Â±SD] factor VIII activity, 12.9Â±6.9% of the normal value at 26 to 52 weeks when the participants were not receiving glucocorticoids vs. 12.0Â±7.1% of the normal value at &gt;52 weeks after vector administration; 95% confidence interval [CI], â2.4 to 0.6 for the difference between matched pairs). The participants had a 91.5% reduction (95% CI, 88.8 to 94.1) in the annualized bleeding rate (median rate, 8.5 events per year [range, 0 to 43.0] before vector administration vs. 0.3 events per year [range, 0 to 6.5] after vector administration).</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Sustained factor VIII expression in 16 of 18 participants who received SPK-8011 permitted discontinuation of prophylaxis and a reduction in bleeding episodes. No major safety concerns were reported. (Funded by Spark Therapeutics and the National Heart, Lung, and Blood Institute; ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT03003533" target="_blank">NCT03003533</a> and <a href="http://clinicaltrials.gov/show/NCT03432520" target="_blank">NCT03432520</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006247/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/7e101bf1-cd37-4294-b99a-ccf2fa772ae2/media/NEJMdo006247_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006247/full/" class="ng-do-media_item-title-link">Factor VIII Expression after Gene Therapy for Hemophilia A</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 1s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Hemophilia A is an X-linked bleeding disorder caused by the deficiency or dysfunction of coagulation factor VIII. Factor VIII, which is endogenously produced primarily in liver sinusoidal endothelial cells, imparts a procoagulant cofactor effect within the intrinsic tenase enzyme complex.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup></div><div role="paragraph">The hemophilia phenotype consists of recurrent joint hemorrhage that, over repeated incidences, results in arthropathy. The hemophilia phenotype correlates with measured plasma factor VIII activity. Spontaneous hemorrhage classically occurs frequently in severe hemophilia (factor VIII activity, &lt;1% of the normal value), infrequently in moderate hemophilia (1 to &lt;5% of the normal value), and rarely in mild hemophilia (5 to &lt;40% of the normal value). Endogenous factor VIII activity greater than 10% of the normal value is associated with a low risk of spontaneous joint bleeding.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-1" href-manipulated="true">3,4</a></sup> Either recurrent intravenous infusion of exogenous factor or subcutaneous administration of a factor VIIIâmimetic bispecific monoclonal antibody, emicizumab, is currently used to confer a moderate or mild hemophilia phenotype in patients with hemophilia A.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r5 r6" id="body-ref-r6-1" href-manipulated="true">3,5,6</a></sup></div><div role="paragraph">Multiple ongoing clinical trials of gene therapy for hemophilia A involve the use of recombinant adeno-associated viral (AAV) vectors to target hepatocyte factor VIII expression with the goal of a one-time disease-altering therapy. Data from an ongoing trial of gene therapy for hemophilia A showed an average decrease of approximately half of transgene expression from year 1 to year 2 after vector administration; the most recently presented 4-year follow-up data showed that this decrease continued.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9" id="body-ref-r9-1" href-manipulated="true">7-9</a></sup> The results of this trial suggested that long-term, stable factor VIII activity may not be achieved with hepatocyte-directed AAV gene transfer in humans. These results were unexpected given observations from clinical trials involving patients with hemophilia B that showed durable factor IX transgene-derived expression for 8 years after hepatocyte-directed AAV-mediated gene transfer and from studies in large-animal models of hemophilia A that showed durable factor VIII transgene-derived expression for 10 years.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12" id="body-ref-r12" href-manipulated="true">10-12</a></sup></div><div role="paragraph">One obstacle to efficacious AAV gene transfer is a cellular immune response against the AAV capsid, which was identified in trials of gene therapy for hemophilia B.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> This response is vector-dose dependent and classically manifested by an increase in the level of the liver enzyme alanine aminotransferase, a decrease in transgene expression, and identification of circulating capsid-specific T cells. Left untreated, this capsid immune response results in complete loss of transgene expression. However, clinical trial results have suggested that this cellular immune response can be controlled by immune suppression in most, but not all, recipients of AAV gene therapy.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16 r17" id="body-ref-r17-1" href-manipulated="true">15-17</a></sup></div><div role="paragraph">We hypothesized that safe and durable hepatocyte expression of factor VIII could provide sufficient endogenous prophylaxis in persons with hemophilia A. Here, we report data from our phase 1â2 trial on the safety and preliminary efficacy of an AAV vector (SPK-8011).</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">This open-label, multicenter, nonrandomized, dose-escalation, phase 1â2 trial evaluated SPK-8011 for hemophilia A. The <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org, was approved by the institutional review board at each investigative site. All the trial participants provided written informed consent for enrollment into one of four dose cohorts, which ranged from a low dose of vector to a high dose (i.e., from 5Ã10<sup>11</sup> vector genomes [vg] per kilogram of body weight to 2Ã10<sup>12</sup> vg per kilogram).</div><div role="paragraph">Immediately before vector administration, the participants received a factor VIII product to attain factor VIII activity that was 100% of the normal value. Thereafter, the participants received a single, intravenous infusion of SPK-8011 on an outpatient basis. Some participants received glucocorticoids within 52 weeks after vector administration either to prevent or to treat a presumed AAV capsid immune response. The participants were followed for 52 weeks after vector administration, and all the participants subsequently were enrolled in a 4-year long-term follow-up trial. The first participant was enrolled on January 26, 2017, and the data cutoff date for the analysis was May 3, 2021.</div><div role="paragraph">The authors designed the trial. Data were collected by clinical site investigators (listed as authors). All the authors analyzed the data and vouch for the accuracy and completeness of the data presented and for the adherence of the trial to the protocol. The first author wrote the first draft of the manuscript with subsequent input from the other authors and without editorial assistance. Previous versions of the figures were developed with editorial assistance funded by Spark Therapeutics, a study sponsor and the vector manufacturer.</div></section><section id="sec-1-2"><h3>Vector Design and Production</h3><div role="paragraph">SPK-8011 is a recombinant-AAV vector consisting of SPK200 (a bioengineered capsid derived from AAV3 [specifically, subtype LK03])<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> with a liver-specific, truncated transthyretin enhancer and promoter, a synthetic intron sequence, and codon-optimized <i>F8</i> complementary DNA encoding FVIII-SQ, a B-domainâdeleted form of factor VIII (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> SPK-8011 was manufactured with transient triple transfection of human embryonic kidney cells (HEK293 cells), and titers were determined by means of quantitative polymerase chain reaction (Supplementary Methods section in the <a href="#ap2">Supplementary Appendix</a>).</div></section><section id="sec-1-3"><h3>Participants</h3><div role="paragraph">We enrolled men (â¥18 years of age) who had congenital hemophilia A and baseline factor VIII activity that was 2% or less of the normal value, no history of factor VIII inhibitory antibodies, and SPK200 neutralizing antibody titers of 1:5 or less. The enrolled participants met all screening criteria outlined in the <a href="#ap2">Supplementary Appendix</a>. Annualized bleeding rates and factor VIII infusions were retrospectively determined by means of review of the participantsâ medical records for the year before enrollment and were compared with prospectively collected phenotypic information after the infusion of vector. Serologic and imaging studies were performed as outlined in the trial protocol.</div></section><section id="sec-1-4"><h3>Objectives</h3><div role="paragraph">The primary objective of the trial was to evaluate the safety and preliminary efficacy of SPK-8011. Safety end points included adverse events and the changes from baseline in findings on physical examination and laboratory values. Efficacy end points included factor VIII activity determined by a central laboratory on the basis of a steady-state one-stage factor VIII assay and the number of factor VIII infusions and bleeding events after vector administration.</div><div role="paragraph">Additional objectives were to characterize expression pharmacokinetics and the immune response to SPK200 and expressed factor VIII-SQ protein. The cellular immune response was assessed by monitoring factor VIII activity, the alanine aminotransferase level, and the participantsâ response to SPK200-derived peptides as determined by an interferon-Î³ enzyme-linked immune absorbent spot (ELISpot) assay of peripheral-blood mononuclear cells (PBMCs).<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-2" href-manipulated="true" aria-label="Reference 16">16</a></sup> Vector shedding was also assessed.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">Descriptive statistics were used to analyze data from all the enrolled participants. For each participant, we used the differences between the mean factor VIII activity in weeks 26 to 52 (when they were not receiving glucocorticoids) and the mean factor VIII activity more than 52 weeks after vector administration to construct a confidence interval for the paired difference. This confidence interval was used to describe the multiyear durability of factor VIII expression. All interval estimates were descriptive in nature to show precision of the estimate; thus, no multiplicity adjustment was performed.</div><div role="paragraph">Prospective bleeding events and factor VIII infusions after the administration of vector were compared with retrospectively collected data and were summarized with means and confidence intervals for the differences. We used Bayesian negative binomial regression with noninformative priors on model parameters to analyze the relationship between the annualized rate of bleeding events after vector administration and the proportion of time the factor VIII activity was greater than 10% of the normal value (as determined in a one-stage factor VIII assay).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Population</h3><div role="paragraph">Of the 34 men with hemophilia A who underwent screening, 18 men (18 to 52 years of age) were enrolled, received vector, and were followed for safety for a median of 36.6 months (range, 5.5 to 50.3) after administration of SPK-8011. Participant 5 was lost to follow-up 32.6 months after administration of vector. All participant data were analyzed (Fig. S2 in the <a href="#ap2">Supplementary Appendix</a>). Thirteen of the 18 participants were receiving factor prophylaxis before vector administration; the remainder received factor VIII on demand. All but 1 participant had baseline hemophilic arthropathy (mean [Â±SD] number of arthropathic joints, 2.8Â±1.7; range, 0 to 6.0). Nine participants had a history of hepatitis C virus infection with baseline stage 0â2 liver fibrosis, and 3 participants had a coexisting human immunodeficiency virus infection (<a href="#t1">Table 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t1.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/c410c551-80b8-4f3f-9c4b-57c0e0652d5a/assets/images/large/nejmoa2104205_t1.jpg" height="3438" width="2595" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxr-borders" colspan="18"><span>SPK-8011 Dose</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>5Ã10<sup>11</sup> vg/kg</span></th><th class="xxxx-borders" colspan="3"><span>1Ã10<sup>12</sup> vg/kg</span></th><th class="xxxx-borders" colspan="9"><span>2Ã10<sup>12</sup> vg/kg</span></th><th class="xxxr-borders" colspan="4"><span>1.5Ã10<sup>12</sup> vg/kg</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="18"><span>participant number</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">1</th><th class="xxxx-borders">2</th><th class="xxxx-borders">3</th><th class="xxxx-borders">4</th><th class="xxxx-borders">6</th><th class="xxxx-borders">5</th><th class="xxxx-borders">7</th><th class="xxxx-borders">8</th><th class="xxxx-borders">9</th><th class="xxxx-borders">10</th><th class="xxxx-borders">11</th><th class="xxxx-borders">12</th><th class="xxxx-borders">13</th><th class="xxxx-borders">14</th><th class="xxxx-borders">15</th><th class="xxxx-borders">16</th><th class="xxxx-borders">17</th><th class="xxxr-borders">18</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>At baseline</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Age â yr</td><td class="xxxx-borders">52</td><td class="xxxx-borders">45</td><td class="xxxx-borders">34</td><td class="xxxx-borders">34</td><td class="xxxx-borders">48</td><td class="xxxx-borders">27</td><td class="xxxx-borders">28</td><td class="xxxx-borders">18</td><td class="xxxx-borders">34</td><td class="xxxx-borders">39</td><td class="xxxx-borders">21</td><td class="xxxx-borders">21</td><td class="xxxx-borders">18</td><td class="xxxx-borders">34</td><td class="xxxx-borders">39</td><td class="xxxx-borders">40</td><td class="xxxx-borders">20</td><td class="xxxr-borders">39</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Weight â kg</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">82</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">60</td><td class="xxxx-borders shading">79</td><td class="xxxx-borders shading">93</td><td class="xxxx-borders shading">72</td><td class="xxxx-borders shading">78</td><td class="xxxx-borders shading">78</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">69</td><td class="xxxx-borders shading">121</td><td class="xxxx-borders shading">60</td><td class="xxxx-borders shading">115</td><td class="xxxx-borders shading">60</td><td class="xxxr-borders shading">95</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">BMI<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">22</td><td class="xxxx-borders">29</td><td class="xxxx-borders">25</td><td class="xxxx-borders">26</td><td class="xxxx-borders">28</td><td class="xxxx-borders">19</td><td class="xxxx-borders">24</td><td class="xxxx-borders">29</td><td class="xxxx-borders">22</td><td class="xxxx-borders">26</td><td class="xxxx-borders">24</td><td class="xxxx-borders">24</td><td class="xxxx-borders">28</td><td class="xxxx-borders">30</td><td class="xxxx-borders">21</td><td class="xxxx-borders">32</td><td class="xxxx-borders">22</td><td class="xxxr-borders">30</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Factor VIII activity â % normal value</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">1â2</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxr-borders shading">&lt;1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Genotype</td><td class="xxxx-borders">Ser1070x</td><td class="xxxx-borders">Arg218<br>2His</td><td class="xxxx-borders">Arg81<br>4x</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Arg301<br>Leu</td><td class="xxxx-borders">Intr 1<br>inv</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Arg21<br>66X</td><td class="xxxx-borders">His855<br>Leufs*2</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Ex<br>20â22<br>del</td><td class="xxxx-borders">Ph2294<br>Serfs*90</td><td class="xxxx-borders">Val402<br>Tyrfs*</td><td class="xxxx-borders">Arg218<br>2His</td><td class="xxxx-borders">Glu98<br>Lys</td><td class="xxxx-borders">Intr 22<br> inv</td><td class="xxxr-borders">Tyr1834<br>Asp</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Cross-reacting material status<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxr-borders shading">+</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Use of prophylaxis</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxr-borders">Yes</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Treatment type</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">pdFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL- rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxr-borders shading">EHL-rFVIII</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Factor VIII dose â IU/kg</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">65 twice weekly</td><td class="xxxx-borders">30 twice weekly</td><td class="xxxx-borders">50 twice weekly and 25 weekly</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">50 every other day</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">25 every other day</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">20 twice weekly</td><td class="xxxx-borders">45 every 4 days</td><td class="xxxx-borders">60 twice weekly</td><td class="xxxx-borders">60 weekly</td><td class="xxxx-borders">40 twice weekly</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">50 weekly</td><td class="xxxx-borders">55 twice weekly</td><td class="xxxr-borders">50 every 5 days</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Arthropathic joints â no.</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">2</td></tr><tr data-type="row"><td class="xxlx-borders">Infection history<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">HCV</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxr-borders shading">+</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">HBV</td><td class="xxxx-borders">â</td><td class="xxxx-borders">+</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">+</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">+</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">HIV</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Liver fibrosis (test)<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">F1<br> (TE)</td><td class="xxxx-borders">F2<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F1âF2<br> (SMF)</td><td class="xxxx-borders">F1<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (TE)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0âF1<br> (SMF)</td><td class="xxxx-borders">F0<br> (APRI)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (APRI)</td><td class="xxxx-borders">F1<br> (TE)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0âF1<br> (SMF)</td><td class="xxxr-borders">F0<br> (SMF)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><b>After gene</b> <b>transfer</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders">Immune suppression</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Use</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxr-borders shading">Yes</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Wk</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">8</td><td class="xxxx-borders">6</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">13</td><td class="xxxx-borders">5</td><td class="xxxx-borders">18</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">8</td><td class="xxxx-borders">14</td><td class="xxxx-borders">16</td><td class="xxxx-borders">44<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">32<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">66<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">52<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxr-borders">3</td></tr><tr data-type="row"><td class="xxlx-borders shading">Factor VIII activity â IU/dl<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Peak</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">OSA</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">25</td><td class="xxxx-borders shading">16</td><td class="xxxx-borders shading">63</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">23</td><td class="xxxx-borders shading">70</td><td class="xxxx-borders shading">22</td><td class="xxxx-borders shading">194</td><td class="xxxx-borders shading">209</td><td class="xxxx-borders shading">43</td><td class="xxxx-borders shading">48</td><td class="xxxx-borders shading">55</td><td class="xxxr-borders shading">94</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">CSA</td><td class="xxxx-borders">10</td><td class="xxxx-borders">8</td><td class="xxxx-borders">5</td><td class="xxxx-borders">15</td><td class="xxxx-borders">14</td><td class="xxxx-borders">16</td><td class="xxxx-borders">37</td><td class="xxxx-borders">20</td><td class="xxxx-borders">8</td><td class="xxxx-borders">15</td><td class="xxxx-borders">46</td><td class="xxxx-borders">16</td><td class="xxxx-borders">117</td><td class="xxxx-borders">117</td><td class="xxxx-borders">29</td><td class="xxxx-borders">29</td><td class="xxxx-borders">38</td><td class="xxxr-borders">70</td></tr><tr data-type="row"><td class="xxlx-borders full shading">Mean, after 52 wk</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">OSA</td><td class="xxxx-borders">11</td><td class="xxxx-borders">8</td><td class="xxxx-borders">5</td><td class="xxxx-borders">8</td><td class="xxxx-borders">22</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">25</td><td class="xxxx-borders">3</td><td class="xxxx-borders">8</td><td class="xxxx-borders">16</td><td class="xxxx-borders">16</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">6</td><td class="xxxx-borders">17</td><td class="xxxx-borders">12</td><td class="xxxx-borders">4</td><td class="xxxx-borders">5</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CSA</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">11</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">11</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders full" data-xml-align="left">Maximum AFP level â ng/ml<a href="#t1fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders">9.0</td><td class="xxxx-borders">3.5</td><td class="xxxx-borders">2.2</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">6.6</td><td class="xxxx-borders">1.8</td><td class="xxxx-borders">4.1</td><td class="xxxx-borders">2.5</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">2.7</td><td class="xxxx-borders">1.6</td><td class="xxxx-borders">2.3</td><td class="xxxx-borders">1.8</td><td class="xxxx-borders">3.7</td><td class="xxxx-borders">3.2</td><td class="xxxx-borders">1.7</td><td class="xxxx-borders">2.6</td><td class="xxxr-borders">8.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders full shading" data-xml-align="left">Duration of safety follow-up â mo</td><td class="xbxx-borders shading">50.3</td><td class="xbxx-borders shading">47.8</td><td class="xbxx-borders shading">45.5</td><td class="xbxx-borders shading">44.2</td><td class="xbxx-borders shading">41.1</td><td class="xbxx-borders shading">32.6</td><td class="xbxx-borders shading">40.9</td><td class="xbxx-borders shading">36.8</td><td class="xbxx-borders shading">36.7</td><td class="xbxx-borders shading">36.5</td><td class="xbxx-borders shading">36.1</td><td class="xbxx-borders shading">35.9</td><td class="xbxx-borders shading">31.7</td><td class="xbxx-borders shading">25.4</td><td class="xbxx-borders shading">23.7</td><td class="xbxx-borders shading">20.7</td><td class="xbxx-borders shading">19.8</td><td class="xbxr-borders shading">5.5</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Participants at Baseline and after Gene Transfer.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">AFP denotes alpha-fetoprotein, APRI aspartate aminotransferaseâto-platelet ratio index, del deletion, EHL extended half-life, ex exon, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, int intron, inv inversion, NA not applicable, pdFVIII, plasma-derived factor VIII, rFVIII, recombinant factor VIII, SMF serum markers of fibrosis, and TE transient elastography.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Positive results (plus sign) for cross-reacting material indicate that FVIII protein is detectable but dysfunctional at baseline, whereas negative results (minus sign) indicate no detectable FVIII protein at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">A positive HCV, HBV, or HIV status (plus sign) indicates that the participant had serologic findings consistent with a history of infection but a negative viral polymerase-chain-reaction test at enrollment. A minus sign indicates that the participant did not have serologic findings consistent with a history of infection.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">Liver fibrosis was assessed on a scale of F0 to F4, with higher stages indicating a greater degree of fibrosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t1fn6" role="paragraph">Participants 14 through 17 received immune suppression for an extended time because of the use of glucocorticoid-sparing agents.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">On the one-stage factor VIII assay (OSA) and chromogenic factor VIII assay (CSA), the normal range for factor VIII activity is 50 to 150 IU per deciliter.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="t1fn8" role="paragraph">The upper limit of the normal range for AFP is 8.9 ng per milliliter.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Safety of SPK-8011 Infusion and Immune-Modulating Agents</h3><div role="paragraph">Participant 5 had an acute infusion reaction involving vomiting, myalgia, back pain, and pyrexia 12 hours after vector administration. This reaction resolved within 72 hours with outpatient antipyretic therapy. Seven participants had elevated alanine aminotransferase levels. All these elevations were mild except in Participant 12, who was hospitalized on an elective basis to receive intravenous methylprednisolone for a grade 2 elevation in the alanine aminotransferase level (3.0 to 4.9 times the upper limit of the normal range); this elevated level constituted the only serious adverse event in the trial (<a href="#t2">Table 2</a>). Among four participants, there were seven nonsustained elevations in alanine aminotransferase levels that met protocol-specified toxicity criteria: six elevations were grade 1 (&gt;2.5 to 2.9 times the upper limit of the normal range), and one elevation was grade 2 (Fig. S3). All these nonsustained elevations in alanine aminotransferase levels occurred in participants in two vector-dose cohorts (1.5Ã10<sup>12</sup> vg per kilogram and 2Ã10<sup>12</sup> vg per kilogram), and these elevations occurred during a cellular immune response against SPK200 that resolved with the use of glucocorticoids.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t2.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/4ba1db0c-4505-4009-809e-bb28e5fe9eff/assets/images/large/nejmoa2104205_t2.jpg" height="2092" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>2Ã10<sup>12</sup> vg/kg Cohort<br>(N=9)</span></th><th class="txxx-borders" colspan="2"><span>1.5Ã10<sup>12</sup> vg/kg Cohort<br>(N=4)</span></th><th class="txxr-borders" colspan="2"><span>All Participants<br> (N=18)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of<br> Participants (%)</th><th class="xxxx-borders">No. of<br> Events</th><th class="xxxx-borders">No. of<br> Participants (%)</th><th class="xxxx-borders">No. of<br> Events</th><th class="xxxx-borders">No. of<br> Participants (%)</th><th class="xxxr-borders">No. of<br> Events</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Adverse event related to SPK-8011</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any event</td><td class="xxxx-borders">4 (44)</td><td class="xxxx-borders">12</td><td class="xxxx-borders">4 (100)</td><td class="xxxx-borders">5</td><td class="xxxx-borders">8 (44)</td><td class="xxxr-borders">17</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Elevated alanine aminotransferase level</td><td class="xxxx-borders shading">3 (33)</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">4 (100)</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">7 (39)</td><td class="xxxr-borders shading">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">1 (11)<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Myalgia</td><td class="xxxx-borders shading">1 (11)<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Back pain</td><td class="xxxx-borders">1 (11)<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">1 (11)<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Serious adverse event related to SPK-8011</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any serious adverse event</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Elevated liver aminotransferase level</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Adverse event related to glucocorticoid</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any event</td><td class="xxxx-borders">2 (22)</td><td class="xxxx-borders">7</td><td class="xxxx-borders">2 (50)</td><td class="xxxx-borders">9</td><td class="xxxx-borders">4 (22)</td><td class="xxxr-borders">16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Adrenal insufficiency</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Gastroesophageal reflux</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Osteoporosis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Weight gain</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">2</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">2 (11)</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Generalized edema</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hypomagnesemia</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Muscle spasms</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Acne</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Irritability</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Psychomotor hyperactivity</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Tremor</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Insomnia</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Hot flash</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (25)</td><td class="xbxx-borders">1</td><td class="xbxx-borders">1 (6)</td><td class="xbxr-borders">1</td></tr></tbody></table></div><figcaption><div class="caption">Drug-Related Adverse Events and Drug-Related Serious Adverse Events.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The relationship between the events and SPK-8011 or glucocorticoid was determined by the clinical investigators. Data are from the safety observation period. There were no drug-related adverse events or serious adverse events in two vector-dose cohorts (5Ã10<sup>11</sup> vg per kilogram and 1Ã10<sup>12</sup> vg per kilogram).</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">One participant had an infusion reaction consisting of pyrexia, myalgia, back pain, and vomiting.</div></div></div></figcaption></figure></div><div role="paragraph">Four participants had adverse events related to glucocorticoids (<a href="#t2">Table 2</a>). Concomitant use of glucocorticoid-sparing immune-modulating agents (e.g., azathioprine, tacrolimus, and mycophenolate mofetil) in some participants did not result in adverse events (Fig. S8). All the participants had vector shedding that was below the quantification limit in saliva, serum, urine, and semen by 3 weeks after vector infusion and in PBMCs by 12 weeks after vector infusion (Fig. S4). Factor VIII inhibitory antibodies did not develop in any of the participants. One participant had an isolated alpha-fetoprotein value of 9.0 ng per milliliter, which is above the upper limit of the normal range (8.9 ng per milliliter) (<a href="#t1">Table 1</a>); this value was within the normal range on repeat analysis. All the other participants had alpha-fetoprotein values that remained within the normal range. No new findings were noted on ultrasonographic assessment of the liver; these assessments were performed to screen for hepatocellular carcinoma, which was identified in preclinical studies as a concern with respect to the long-term safety of systemic administration of AAV.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21" id="body-ref-r21" href-manipulated="true">20,21</a></sup></div></section><section id="sec-2-3"><h3>Factor VIII Expression and Durability</h3><div role="paragraph">All the participants had factor VIII expression after vector administration. Two of the 18 participants, both of whom were in the cohort that received 2Ã10<sup>12</sup> vg per kilogram, lost expression after a cellular immune response against SPK200 detailed below and in the Supplementary Results section in the <a href="#ap2">Supplementary Appendix</a>. Among the 15 participants in whom factor VIII expression was maintained and who were followed for more than 52 weeks, the mean factor VIII activity more than 52 weeks after vector administration was 11.0Â±6.8% of the normal value (range, 3.2 to 24.8) in a one-stage factor VIII assay and 6.9Â±3.8% of the normal value (range, 3.0 to 14.3) in a chromogenic factor VIII assay. Consistent with findings in other trials of therapy for hemophilia A,<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r22" id="body-ref-r22" href-manipulated="true">7,22</a></sup> factor VIII activity that was determined with the use of a one-stage factor VIII assay was 1.5 times as high as that determined with the use of a chromogenic factor VIII assay (Fig. S5).</div><div role="paragraph">Across all the dose cohorts, the initial peak factor VIII expression occurred 6 to 12 weeks after vector administration (<a href="#f1">Figure 1</a> and Figs. S6 though S8). Participants in the cohorts that received 5Ã10<sup>11</sup> vg per kilogram or 1Ã10<sup>12</sup> vg per kilogram reached plateau factor VIII activity by 12 weeks; these kinetics of expression are consistent with previous observations in trials of AAV gene therapy for hemophilia B.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-3" href-manipulated="true" aria-label="Reference 16">16</a></sup> In contrast, participants in the cohorts that received 1.5Ã10<sup>12</sup> vg per kilogram or 2Ã10<sup>12</sup> vg per kilogram (except Participant 6) had decreases in peak expression from week 6 to 12 to plateau expression by 26 to 52 weeks after vector administration. Although peak expression in the cohorts that received 5Ã10<sup>11</sup> vg per kilogram or 1Ã10<sup>12</sup> vg per kilogram was lower than that observed in the cohorts that received 1.5Ã10<sup>12</sup> vg per kilogram or 2Ã10<sup>12</sup> vg per kilogram, a clear dose response in steady-state factor VIII activity was not observed more than 52 weeks after vector administration. This finding may be related to a narrow dose escalation, interparticipant variability, or both that have been observed in previous trials of gene therapy for hemophilia.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r16" id="body-ref-r16-4" href-manipulated="true">8,16</a></sup></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f1.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/a328bc7e-d37f-4c93-bb5b-8f166c22c7a7/assets/images/large/nejmoa2104205_f1.jpg" height="1520" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Factor VIII Activity after Infusion of SPK-8011 in 18 Participants.</div><div class="notes"><div role="doc-footnote">The SPK-8011 vector was administered in four doses: 5Ã10<sup>11</sup> vector genomes (vg) per kilogram of body weight, 1Ã10<sup>12</sup> vg per kilogram, 1.5Ã10<sup>12</sup> vg per kilogram, and 2Ã10<sup>12</sup> vg per kilogram. On the y axis, factor VIII activity is shown on a log scale. The number to the right of each line is the participant number. Factor VIII activity was determined with the use of a one-stage factor VIII assay. The gray shaded area indicates the range of factor VIII activity in mild hemophilia A. Participants 5 and 12 lost transgene expression.</div></div></figcaption></figure></div><div role="paragraph">Among the 16 participants in whom factor VIII expression was maintained outside the capsid immune response window, 12 were followed for more than 2 years and had apparent multiyear stable expression. Specifically, for the difference between matched pairs (i.e., an individual participantâs mean factor VIII activity when not receiving glucocorticoids during the period from 26 to 52 weeks vs. that participantâs mean factor VIII activity after 52 weeks), the confidence interval was â2.4 to 0.6 (<a href="#f1">Figure 1</a> and Table S1). In addition, among these 12 men, the combined mean factor VIII activity when the participants were not receiving glucocorticoids for 26 to 52 weeks (12.9Â±6.9% of the normal value) was analogous to the combined mean factor VIII activity after more than 52 weeks (12.0Â±7.1%).</div></section><section id="sec-2-4"><h3>Cellular Immune Response against the AAV Capsid and Immune Modulation Course</h3><div role="paragraph">The initial dosing protocol called for the first 12 participants to receive glucocorticoids when at least one of the following trial assessments indicated a capsid immune response: a decrease in factor VIII activity, an increase in the alanine aminotransferase level to at least 1.5 times the level at baseline, or a positive PBMC interferon-Î³ ELISpot to SPK200 peptides. Five participants did not receive glucocorticoids. Eight participants received glucocorticoids for 3 to 18 weeks (within the first 52 weeks after vector infusion), and vector expression was maintained in 6 of these participants. Although they received glucocorticoids, Participants 5 and 12 lost all factor VIII expression within 52 weeks after vector infusion because of a capsid immune response; emicizumab was initiated in Participant 5, and the use of factor VIII prophylaxis was resumed in Participant 12.</div><div role="paragraph">In response to the loss of factor VIII expression in two participants, the protocol was amended, and the subsequent five participants (Participants 13 through 17) received prophylactic glucocorticoids that were initiated early (2 to 4 weeks after vector administration); transgene expression was maintained in all these participants. However, attempts to wean four of these participants (Participants 14 through 17) off oral glucocorticoids resulted in an increase in the alanine aminotransferase level, positive SPK200 ELISpot assays, or both outside the 3-month window that is typical of a capsid cellular immune response. Thus, in Participants 14 through 17, treatment was transitioned to glucocorticoid-sparing immune-modulating agents (azathioprine or mycophenolate mofetil, tacrolimus, or both) for a total of 32 to 66 weeks, and factor VIII expression was maintained when the participants were weaned off all immune-modulating agents (<a href="#t1">Table 1</a>). Because of the prolonged use of immune modulation in the participants who received prophylactic glucocorticoids, Participant 18 received glucocorticoids when evidence of an immune response to the vector was noted and expression was maintained. Consistent with the presence of a glucocorticoid response element in the promoter, factor VIII expression increased in all the participants while they were receiving glucocorticoids.</div></section><section id="sec-2-5"><h3>Preliminary Efficacy of SPK-8011</h3><div role="paragraph">The analysis involving all 18 participants (median efficacy follow-up, 33.4 months; range, 3.7 to 47.6) showed a 91.5% reduction (95% confidence interval [CI], 88.8 to 94.1) in the annualized rate of bleeding events (median, 8.5 events per year [range, 0 to 43] before vector administration vs. 0.3 events per year [range, 0 to 6.5] after vector administration) (<a href="#f2">Figure 2A</a>) and a 96.4% reduction (95% CI, 95.7 to 97.1) in the annualized number of factor VIII infusions (median, 57.5 infusions [range, 24 to 245] per year before vector administration vs. 0.6 [range, 0 to 28.6] after administration) (<a href="#f2">Figure 2B</a>). For Participants 5 and 12, the reported efficacy data were based on observations before loss of factor VIII expression. The percentage of participants with no bleeding events ranged from 60 to 100% at years 1 through 4 of follow-up (<a href="#f2">Figure 2C</a>), and the cumulative percentage was 39% over the entire follow-up period (<a href="#f2">Figure 2A</a>). Prophylaxis was discontinued in the 16 participants who had sustained factor VIII expression.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f2.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/24e3a46a-2c39-44fa-9967-87ffd6354507/assets/images/large/nejmoa2104205_f2.jpg" height="3438" width="2630" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Preliminary Efficacy of SPK-8011.</div><div class="notes"><div role="doc-footnote">Panel A shows the annualized rate of bleeding events before and after vector infusion. Panel B shows the annualized number of exogenous factor VIII infusions before and after vector infusion. Participants 5 and 12 lost all transgene expression within 1 year after vector administration, and the data shown are for the period of transgene expression only. Panel C shows the percentage of participants with no bleeding events after SPK-8011 administration. The number of participants who completed each follow-up interval is indicated below the x-axis.</div></div></figcaption></figure></div><div role="paragraph">A Bayesian negative binomial regression analysis showed that the mean spontaneous bleeding rates were less than 1 event per year, with a posterior probability of 0.99 when transgene-derived factor VIII activity was more than 10% of the normal value at least 50% of the time in a one-stage factor VIII assay (<a href="#f3">Figure 3</a>). These data indicate that among participants who had factor VIII activity that was greater than 10% of the normal value in a one-stage factor VIII assay at least half the time, the probability of an annualized rate of bleeding events of less than 1 event was 99%.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f3.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/fb1ad4aa-728b-42da-ba6a-fa2d82ddc352/assets/images/large/nejmoa2104205_f3.jpg" height="3438" width="2126" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Correlation between Factor VIII Activity and the Rate of Spontaneous Bleeding Events.</div><div class="notes"><div role="doc-footnote">Panel A shows the factor VIII activity relative to the annualized rate of spontaneous bleeding among Participants 1 through 18. Factor VIII activity was determined with the use of a one-stage factor VIII assay. A Bayesian negative binomial regression analysis with noninformative priors was used to analyze the relationship between the annualized rate of spontaneous bleeding after vector administration and the proportion of time participants had factor VIII activity that was greater than 10% of the normal value. The blue curve indicates the regression line, and the shaded area the 95% credible interval. Each X denotes one participant, and the participant numbers are shown. Data shown for Participants 5 and 12 are based on observations before the loss of transgene expression. Panel B shows the posterior density of the mean annualized rate of spontaneous bleeding among participants with factor VIII activity of more than 10% of the normal value at least half the time; among these participants, there was a 99% probability of an annualized rate of spontaneous bleeding of less than 1 event. The gray vertical line indicates an annualized rate of spontaneous bleeding of 1 event.</div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">Our phase 1â2 trial data showed that SPK-8011 imparted multiyear durable factor VIII expression that significantly reduced bleeding. These data provide support for our hypothesis that hepatocyte expression of factor VIII after AAV gene transfer is a viable approach for long-term stable phenotypic amelioration of hemophilia A.</div><div role="paragraph">No major safety concerns were identified after the administration of SPK-8011. In our trial, nonsustained, drug-related elevations in alanine aminotransferase levels that met toxicity criteria (&gt;2.5 to 3.6 times the upper limit of the normal range) occurred in 22% of the participants who had a cellular immune response against SPK200. These findings are consistent with the results of previous trials of AAV-mediated gene therapy for hemophilia B<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16" id="body-ref-r16-5" href-manipulated="true">15,16</a></sup> and contrast with the elevated alanine aminotransferase levels of unclear cause lasting for multiple months that were observed in a previous trial of AAV5-hFVIII-SQ gene therapy for hemophilia A.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-3" href-manipulated="true">7,8</a></sup> Although the suspected immune response against SPK200 did not arouse major safety concerns, it limited the efficacy of SPK-8011 in some participants.</div><div role="paragraph">The complete loss of factor VIII expression in two participants in the highest-dose cohort showed that the AAV capsid immune response was not universally sensitive to glucocorticoids; this observation was noted in another trial of AAV gene transfer.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-2" href-manipulated="true" aria-label="Reference 17">17</a></sup> Although the use of prophylactic glucocorticoids prevented loss of expression, attempts to wean participants from these agents were complicated by the recurrence of laboratory findings that were consistent with a cellular immune response. However, in a small cohort, the use of azathioprine or tacrolimus, with or without mycophenolate mofetil, enabled participants to discontinue glucocorticoids and allowed for maintenance of transgene expression; further evaluation in a larger cohort is necessary before conclusions can be drawn.</div><div role="paragraph">The effect of immune suppression on the clearance of the AAV capsid antigen and the consequent duration of the presence of antigen after vector administration are unknown. Similarly, aside from the CpG (cytosineâguanine dinucleotide) content in the vector cassette,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-3" href-manipulated="true" aria-label="Reference 17">17</a></sup> whether the capsid serotype, the manufacturing method, or both play a role in the incidence and severity of a capsid immune response has not been established.</div><div role="paragraph">As expected, a small amount of durable factor VIII expression conferred a marked clinical benefit in the 15 participants with sustained factor VIII expression who were followed for more than 52 weeks. Specifically, transgene-derived factor VIII activity that was greater than 10% of the normal value in a one-stage factor VIII assay eliminated spontaneous joint bleeding; this finding is consistent with natural history data indicating a relationship between joint bleeding and the activity of endogenous factor VIII determined by a one-stage factor VIII assay in persons with hemophilia.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> Thus, factor VIII activity that was determined by a one-stage factor VIII assay may correlate with the in vivo hemostatic effect of hepatocyte-derived factor VIII. Furthermore, the observed annualized bleeding rate of 0 events in 60 to 100% of 16 participants with sustained factor VIII expression is similar to the results with emicizumab prophylaxis in severe hemophilia A.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6-2" href-manipulated="true" aria-label="Reference 6">6</a></sup> Collectively, these data suggest that multiyear, durable factor VIII expression of greater than 10% as determined by a one-stage factor VIII assay may be a threshold for minimally targeted therapeutic efficacy after gene transfer and may confer a phenotype analogous to emicizumab prophylaxis.</div><div role="paragraph">The multiyear, generally stable hepatocyte factor VIII expression observed in our trial contrasts with expression in a hemophilia A gene-transfer trial evaluating AAV5-hFVIII-SQ in which approximately half of transgene expression was lost in nearly all participants from year 1 to year 2 after vector infusion and in which expression continued to decrease throughout the 4 years of available follow-up.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9" id="body-ref-r9-2" href-manipulated="true">7-9</a></sup> Both vectors encode the same B-domainâdeleted factor VIII variant (FVIII-SQ). AAV5-hFVIII-SQ differs from SPK-8011 in that it was manufactured with baculovirus transduction of <i>Spodoptera frugiperda</i> (Sf9) cells. In addition, AAV5-hFVIII-SQ differs from SPK-8011 with respect to codon optimization of the expression cassette, AAV capsid serotype, vector dose (30 to 120 times as high with AAV5-hFVIII-SQ), and the promoter.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-5" href-manipulated="true">7,8</a></sup></div><div role="paragraph">Previous AAV gene-therapy studies of hemophilia B that used an AAV serotype 5 vector manufactured with the baculovirus vector-production system and administered at doses that were similar to those of AAV5-hFVIII-SQ<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-6" href-manipulated="true">7,8</a></sup> showed stable factor IX protein expression in participants for more than 2 years<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> after vector administration. These findings suggest that the capsid, manufacturing platform, or vector dose alone is not responsible for differences in the durability of factor VIII expression across trials of gene therapy for hemophilia A. Furthermore, both SPK-8011 and AAV5-hFVIII-SQ have cassette sizes of approximately 5 kb, so the length of DNA packaged is not different; whether other factors (e.g., charge differences in the capsid sequence) affect DNA packaging, inverted terminal repeatâdependent formation of stable concatemers, or both is unclear.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> Although both vectors used promoters targeting hepatocyte expression of factor VIII, cell-specific expression was not confirmed, which leaves open the possibility that expression from heterogeneous cell sources may account for differences in durability.</div><div role="paragraph">Finally, on average, AAV5-hFVIII-SQ was associated with factor VIII activity that was 10 times as high at 1 year after vector administration as that of SPK-8011.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9" id="body-ref-r9-3" href-manipulated="true">8,9</a></sup> This outcome was not unexpected given that vector doses of AAV5-hFVIII-SQ were orders of magnitude higher than those of SPK-8011. This finding raises the possibility that the level of factor VIII expression itself may contribute to durability. One proposed explanation is that factor VIII expression induces an unfolded protein response that, unmitigated, can produce apoptosis and loss of expression<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup>; this has been observed in factor VIII mammalian cell culture and with supratherapeutic, but not low, levels of factor VIII expression after liver-directed gene transfer with AAV vectors in mice.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27 r28 r29 r30 r31" id="body-ref-r31" href-manipulated="true">26-31</a></sup></div><div role="paragraph">Although SPK-8011 led to stable expression of factor VIII after gene transfer in most participants, a presumed dose-dependent capsid immune response prevented sustained expression in 2 of 18 participants. The safe achievement of sustained, stable, and predictable factor VIII levels in all participants, even in the presence of immune responses, remains an unrealized goal of gene therapy for hemophilia A. Potential solutions are under investigation and may include the use of less immunogenic AAV capsids,<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> gain-of-function factor VIII transgenes,<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33 r34 r35" id="body-ref-r35" href-manipulated="true">33-35</a></sup> improved immune modulation regimens, or all of these.</div><div role="paragraph">Our trial provided data on multiyear, stable factor VIII expression after hepatocyte-directed AAV gene transfer. This trial began to answer questions that have emerged from previous trials of AAV-mediated gene transfer for hemophilia A. Close monitoring of participants to determine safety and efficacy and to confirm initial multiyear observations of durable expression are ongoing.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Spark Therapeutics</span> and grants from the National Heart, Lung, and Blood Institute (NIH/<span class="named-content" data-type="funder">NHLBI</span> K08 HL 146991, to Dr. George, and NIH/<span class="named-content" data-type="funder">NHLBI</span> K08 HL 140078, to Dr. Samelson-Jones).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2104205_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104205/suppl_file/nejmoa2104205_research-summary.pdf" download="nejmoa2104205_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104205_research-summary.pdf" data-doi="10.1056/NEJMoa2104205">Download</a></li><li>487.63 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2104205_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104205/suppl_file/nejmoa2104205_protocol.pdf" download="nejmoa2104205_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104205_protocol.pdf" data-doi="10.1056/NEJMoa2104205">Download</a></li><li>7.62 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2104205_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104205/suppl_file/nejmoa2104205_appendix.pdf" download="nejmoa2104205_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104205_appendix.pdf" data-doi="10.1056/NEJMoa2104205">Download</a></li><li>1.85 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2104205_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104205/suppl_file/nejmoa2104205_disclosures.pdf" download="nejmoa2104205_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104205_disclosures.pdf" data-doi="10.1056/NEJMoa2104205">Download</a></li><li>999.10 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2104205_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104205/suppl_file/nejmoa2104205_data-sharing.pdf" download="nejmoa2104205_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104205_data-sharing.pdf" data-doi="10.1056/NEJMoa2104205">Download</a></li><li>70.19 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Everett LA, Cleuren ACA, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. <em>Blood</em> 2014;123:3697-3705.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-02-554501" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24719406/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342617200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Murine+coagulation+factor+VIII+is+synthesized+in+endothelial+cells.&amp;publication_year=2014&amp;journal=Blood&amp;pages=3697-3705&amp;doi=10.1182%2Fblood-2014-02-554501&amp;pmid=24719406" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. <em>Blood</em> 2014;123:3706-3713.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-02-555151" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24705491/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342617200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+conditional+knockout+mouse+model+reveals+endothelial+cells+as+the+principal+and+possibly+exclusive+source+of+plasma+factor+VIII.&amp;publication_year=2014&amp;journal=Blood&amp;pages=3706-3713&amp;doi=10.1182%2Fblood-2014-02-555151&amp;pmid=24705491" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Mannucci PM, Tuddenham EG. The hemophilias â from royal genes to gene therapy. <em>N Engl J Med</em> 2001;344:1773-1779.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJM200106073442307&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11396445/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000169133600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+hemophilias+%E2%80%94+from+royal+genes+to+gene+therapy.&amp;publication_year=2001&amp;journal=N+Engl+J+Med&amp;pages=1773-1779&amp;doi=10.1056%2FNEJM200106073442307&amp;pmid=11396445" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a low risk of spontaneous joint bleeding. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] phenotype in patients with hemophilia A. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. <em>Haemophilia</em> 2011;17:41-44.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2516.2010.02383.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20825504/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285762900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analysis+of+low+frequency+bleeding+data%3A+the+association+of+joint+bleeds+according+to+baseline+FVIII+activity+levels.&amp;publication_year=2011&amp;journal=Haemophilia&amp;pages=41-44&amp;doi=10.1111%2Fj.1365-2516.2010.02383.x&amp;pmid=20825504" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a low risk of spontaneous joint bleeding. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] VIII assay in persons with hemophilia. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. <em>N Engl J Med</em> 2007;357:535-544.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa067659&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17687129/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248584900004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prophylaxis+versus+episodic+treatment+to+prevent+joint+disease+in+boys+with+severe+hemophilia.&amp;publication_year=2007&amp;journal=N+Engl+J+Med&amp;pages=535-544&amp;doi=10.1056%2FNEJMoa067659&amp;pmid=17687129" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. <em>N Engl J Med</em> 2018;379:811-822.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1803550&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30157389/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443047800005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emicizumab+prophylaxis+in+patients+who+have+hemophilia+A+without+inhibitors.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=811-822&amp;doi=10.1056%2FNEJMoa1803550&amp;pmid=30157389" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] phenotype in patients with hemophilia A. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] prophylaxis in severe hemophilia A. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. <em>N Engl J Med</em> 2017;377:2519-2530.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1708483&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29224506/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000418777700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=AAV5-factor+VIII+gene+transfer+in+severe+hemophilia+A.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2519-2530&amp;doi=10.1056%2FNEJMoa1708483&amp;pmid=29224506" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] data showed that this decrease continued. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] other trials of therapy for hemophilia A, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] gene therapy for hemophilia A. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the 4 years of available follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] with AAV5-hFVIII-SQ), and the promoter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] were similar to those of AAV5-hFVIII-SQ </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. <em>N Engl J Med</em> 2020;382:29-40.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1908490&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31893514/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505606700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiyear+follow-up+of+AAV5-hFVIII-SQ+gene+therapy+for+hemophilia+A.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=29-40&amp;doi=10.1056%2FNEJMoa1908490&amp;pmid=31893514" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] data showed that this decrease continued. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] trials of gene therapy for hemophilia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] gene therapy for hemophilia A. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the 4 years of available follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] with AAV5-hFVIII-SQ), and the promoter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] were similar to those of AAV5-hFVIII-SQ </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] vector administration as that of SPK-8011. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Pasi KJ, Rangarajan S, Mitchell N, et al. A first-in-human four-year follow-up study of durable therapeutic efficacy and safety of AAV gene therapy with valoctocogene roxaparvovec for severe haemophilia A. <em>Haemophilia</em> 2020;26:Suppl 4:151-151. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31859415/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503505000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+first-in-human+four-year+follow-up+study+of+durable+therapeutic+efficacy+and+safety+of+AAV+gene+therapy+with+valoctocogene+roxaparvovec+for+severe+haemophilia+A.&amp;publication_year=2020&amp;journal=Haemophilia&amp;pages=151-151&amp;pmid=31859415" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] data showed that this decrease continued. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the 4 years of available follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] vector administration as that of SPK-8011. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. <em>N Engl J Med</em> 2014;371:1994-2004.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1407309&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25409372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345002900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+safety+and+efficacy+of+factor+IX+gene+therapy+in+hemophilia+B.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1994-2004&amp;doi=10.1056%2FNEJMoa1407309&amp;pmid=25409372" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Nathwani ACRU, Tuddenham E, Chowdary P, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removingâ empty viral particlesâ on safety and efficacy of gene transfer. <em>Blood</em> 2019;132:491-491. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2018-99-118334" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454837601200" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adeno-associated+mediated+gene+transfer+for+hemophilia+B%3A+8+year+follow+up+and+impact+of+removing%E2%80%9D+empty+viral+particles%E2%80%9D+on+safety+and+efficacy+of+gene+transfer.&amp;publication_year=2019&amp;journal=Blood&amp;pages=491-491&amp;doi=10.1182%2Fblood-2018-99-118334" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Nguyen GN, Everett JK, Kafle S, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. <em>Nat Biotechnol</em> 2021;39:47-55.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41587-020-0741-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33199875/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000590031600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+long-term+study+of+AAV+gene+therapy+in+dogs+with+hemophilia+A+identifies+clonal+expansions+of+transduced+liver+cells.&amp;publication_year=2021&amp;journal=Nat+Biotechnol&amp;pages=47-55&amp;doi=10.1038%2Fs41587-020-0741-7&amp;pmid=33199875" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. <em>Nat Med</em> 2007;13:419-422.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm1549" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17369837/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245543900029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CD8%28%2B%29+T-cell+responses+to+adeno-associated+virus+capsid+in+humans.&amp;publication_year=2007&amp;journal=Nat+Med&amp;pages=419-422&amp;doi=10.1038%2Fnm1549&amp;pmid=17369837" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. <em>Nat Med</em> 2006;12:342-347.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm1358" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16474400/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000235802900035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Successful+transduction+of+liver+in+hemophilia+by+AAV-factor+IX+and+limitations+imposed+by+the+host+immune+response.&amp;publication_year=2006&amp;journal=Nat+Med&amp;pages=342-347&amp;doi=10.1038%2Fnm1358&amp;pmid=16474400" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. <em>N Engl J Med</em> 2011;365:2357-2365.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1108046&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22149959/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000298320200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adenovirus-associated+virus+vector-mediated+gene+transfer+in+hemophilia+B.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=2357-2365&amp;doi=10.1056%2FNEJMoa1108046&amp;pmid=22149959" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not all, recipients of AAV gene therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] AAV-mediated gene therapy for hemophilia B </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. <em>N Engl J Med</em> 2017;377:2215-2227.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1708538&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29211678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417201100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemophilia+B+gene+therapy+with+a+high-specific-activity+factor+IX+variant.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2215-2227&amp;doi=10.1056%2FNEJMoa1708538&amp;pmid=29211678" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not all, recipients of AAV gene therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] peripheral-blood mononuclear cells (PBMCs). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of AAV gene therapy for hemophilia B. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] trials of gene therapy for hemophilia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] AAV-mediated gene therapy for hemophilia B </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. <em>Blood</em> 2021;137:763-774.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004625" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33067633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000617757100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BAX+335+hemophilia+B+gene+therapy+clinical+trial+results%3A+potential+impact+of+CpG+sequences+on+gene+expression.&amp;publication_year=2021&amp;journal=Blood&amp;pages=763-774&amp;doi=10.1182%2Fblood.2019004625&amp;pmid=33067633" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not all, recipients of AAV gene therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in another trial of AAV gene transfer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] content in the vector cassette, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. <em>Nature</em> 2014;506:382-386.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature12875" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24390344/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000331477800044" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Selection+and+evaluation+of+clinically+relevant+AAV+variants+in+a+xenograft+liver+model.&amp;publication_year=2014&amp;journal=Nature&amp;pages=382-386&amp;doi=10.1038%2Fnature12875&amp;pmid=24390344" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Anguela XM, Shen SH. CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders. U.S. patent application no. 0216408A1. August 3, 2017.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CpG+reduced+factor+VIII+variants%2C+compositions+and+methods+and+uses+for+treatment+of+hemostasis+disorders&amp;publication_year=2017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. <em>J Clin Invest</em> 2015;125:870-880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI79213" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25607839/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348962700040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vector+design+influences+hepatic+genotoxicity+after+adeno-associated+virus+gene+therapy.&amp;publication_year=2015&amp;journal=J+Clin+Invest&amp;pages=870-880&amp;doi=10.1172%2FJCI79213&amp;pmid=25607839" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. <em>Science</em> 2007;317:477-477.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1142658" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17656716/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248339800034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=AAV+vector+integration+sites+in+mouse+hepatocellular+carcinoma.&amp;publication_year=2007&amp;journal=Science&amp;pages=477-477&amp;doi=10.1126%2Fscience.1142658&amp;pmid=17656716" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Konkle BASK, Visweshwar N, Harrington TJ, et al. Updated follow-up of the Alta study, a phase 1/2, open-label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy. <em>Blood</em> 2019;134:Suppl 1:2060-2060. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2019-122143" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577160404018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+follow-up+of+the+Alta+study%2C+a+phase+1%2F2%2C+open-label%2C+adaptive%2C+dose-ranging+study+to+assess+the+safety+and+tolerability+of+SB-525+gene+therapy.&amp;publication_year=2019&amp;journal=Blood&amp;pages=2060-2060&amp;doi=10.1182%2Fblood-2019-122143" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Miesbach WMK, Coppens M, Kampmann P, et al. Stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 4 years following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B. <em>Blood</em> 2019;134:Suppl 1:2059-2059. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2019-122535" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31697809/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577160404017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stable+FIX+expression+and+durable+reductions+in+bleeding+and+factor+IX+consumption+for+up+to+4+years+following+AMT-060+gene+therapy+in+adults+with+severe+or+moderate-severe+hemophilia+B.&amp;publication_year=2019&amp;journal=Blood&amp;pages=2059-2059&amp;doi=10.1182%2Fblood-2019-122535&amp;pmid=31697809" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. <em>J Virol</em> 2005;79:9933-9944.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.79.15.9933-9944.2005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16014954/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230575300055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Packaging+capacity+of+adeno-associated+virus+serotypes%3A+impact+of+larger+genomes+on+infectivity+and+postentry+steps.&amp;publication_year=2005&amp;journal=J+Virol&amp;pages=9933-9944&amp;doi=10.1128%2FJVI.79.15.9933-9944.2005&amp;pmid=16014954" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. <em>Science</em> 2011;334:1081-1086.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1209038" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22116877/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297313900038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+unfolded+protein+response%3A+from+stress+pathway+to+homeostatic+regulation.&amp;publication_year=2011&amp;journal=Science&amp;pages=1081-1086&amp;doi=10.1126%2Fscience.1209038&amp;pmid=22116877" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Malhotra JD, Miao H, Zhang K, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. <em>Proc Natl Acad Sci U S A</em> 2008;105:18525-18530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0809677105" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19011102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261489300087" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antioxidants+reduce+endoplasmic+reticulum+stress+and+improve+protein+secretion.&amp;publication_year=2008&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=18525-18530&amp;doi=10.1073%2Fpnas.0809677105&amp;pmid=19011102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Lange AM, Altynova ES, Nguyen GN, Sabatino DE. Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. <em>Mol Ther Methods Clin Dev</em> 2016;3:16064-16064.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/mtm.2016.64" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27738645/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393455200054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overexpression+of+factor+VIII+after+AAV+delivery+is+transiently+associated+with+cellular+stress+in+hemophilia+A+mice.&amp;publication_year=2016&amp;journal=Mol+Ther+Methods+Clin+Dev&amp;pages=16064-16064&amp;doi=10.1038%2Fmtm.2016.64&amp;pmid=27738645" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Poothong J, Pottekat A, Siirin M, et al. Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. <em>Blood</em> 2020;135:1899-1911.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019002867" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32128578/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535968000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+VIII+exhibits+chaperone-dependent+and+glucose-regulated+reversible+amyloid+formation+in+the+endoplasmic+reticulum.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1899-1911&amp;doi=10.1182%2Fblood.2019002867&amp;pmid=32128578" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Becker S, Simpson JC, Pepperkok R, et al. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. <em>Thromb Haemost</em> 2004;92:23-35.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1160/TH03-06-0360" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15213841/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000222711200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Confocal+microscopy+analysis+of+native%2C+full+length+and+B-domain+deleted+coagulation+factor+VIII+trafficking+in+mammalian+cells.&amp;publication_year=2004&amp;journal=Thromb+Haemost&amp;pages=23-35&amp;doi=10.1160%2FTH03-06-0360&amp;pmid=15213841" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Brown HC, Gangadharan B, Doering CB. Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response. <em>J Biol Chem</em> 2011;286:24451-24457.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1074/jbc.M111.238758" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21606503/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292294900085" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Enhanced+biosynthesis+of+coagulation+factor+VIII+through+diminished+engagement+of+the+unfolded+protein+response.&amp;publication_year=2011&amp;journal=J+Biol+Chem&amp;pages=24451-24457&amp;doi=10.1074%2Fjbc.M111.238758&amp;pmid=21606503" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Zolotukhin I, Markusic DM, Palaschak B, Hoffman BE, Srikanthan MA, Herzog RW. Potential for cellular stress response to hepatic factor VIII expression from AAV vector. <em>Mol Ther Methods Clin Dev</em> 2016;3:16063-16063.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/mtm.2016.63" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27738644/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393455200053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Potential+for+cellular+stress+response+to+hepatic+factor+VIII+expression+from+AAV+vector.&amp;publication_year=2016&amp;journal=Mol+Ther+Methods+Clin+Dev&amp;pages=16063-16063&amp;doi=10.1038%2Fmtm.2016.63&amp;pmid=27738644" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Chan YK, Wang SK, Chu CJ, et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. <em>Sci Transl Med</em> 2021;13:eabd3438-eabd3438.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.abd3438" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33568518/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000617688400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Engineering+adeno-associated+viral+vectors+to+evade+innate+immune+and+inflammatory+responses.&amp;publication_year=2021&amp;journal=Sci+Transl+Med&amp;pages=eabd3438-eabd3438&amp;doi=10.1126%2Fscitranslmed.abd3438&amp;pmid=33568518" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Samelson-Jones BJ, Arruda VR. Protein-engineered coagulation factors for hemophilia gene therapy. <em>Mol Ther Methods Clin Dev</em> 2018;12:184-201.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.omtm.2018.12.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30705923/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461055600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Protein-engineered+coagulation+factors+for+hemophilia+gene+therapy.&amp;publication_year=2018&amp;journal=Mol+Ther+Methods+Clin+Dev&amp;pages=184-201&amp;doi=10.1016%2Fj.omtm.2018.12.007&amp;pmid=30705923" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Simioni P, Cagnin S, Sartorello F, et al. Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. <em>Blood</em> 2021;137:2383-2393.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2020008168" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33275657/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000646140000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Partial+F8+gene+duplication+%28factor+VIII+Padua%29+associated+with+high+factor+VIII+levels+and+familial+thrombophilia.&amp;publication_year=2021&amp;journal=Blood&amp;pages=2383-2393&amp;doi=10.1182%2Fblood.2020008168&amp;pmid=33275657" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Wilhelm AR, Parsons NA, Samelson-Jones BJ, et al. Activated protein C has a regulatory role in factor VIII function. <em>Blood</em> 2021;137:2532-2543.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2020007562" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33512448/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000648518900014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Activated+protein+C+has+a+regulatory+role+in+factor+VIII+function.&amp;publication_year=2021&amp;journal=Blood&amp;pages=2532-2543&amp;doi=10.1182%2Fblood.2020007562&amp;pmid=33512448" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/21"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">21</span></span> â¢ <span property="datePublished">November 18, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1961</span>-<span property="pageEnd">1973</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2104205" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2104205?sg=AbW1N">Chinese Translation ä¸­æç¿»è¯</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: November 17, 2021</div><div><b class="core-label">Published in issue</b>: November 18, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/anticoagulation-thromboembolism-cardiology" alt="View article keyword Anticoagulation/Thromboembolism (Cardiology)" data-interactiontype="article_recirculation_click">Anticoagulation/Thromboembolism (Cardiology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/coagulation" alt="View article keyword Coagulation" data-interactiontype="article_recirculation_click">Coagulation</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/genetics-general" alt="View article keyword Genetics General" data-interactiontype="article_recirculation_click">Genetics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pediatrics-general" alt="View article keyword Pediatrics General" data-interactiontype="article_recirculation_click">Pediatrics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Lindsey A.</span> <span property="familyName">George</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Paul E.</span> <span property="familyName">Monahan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">M. Elaine</span> <span property="familyName">Eyster</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Spencer K.</span> <span property="familyName">Sullivan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Margaret V.</span> <span property="familyName">Ragni</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stacy E.</span> <span property="familyName">Croteau</span>, <span property="honorificSuffix">M.D., M.M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">John E.J.</span> <span property="familyName">Rasko</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael</span> <span property="familyName">Recht</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Benjamin J.</span> <span property="familyName">Samelson-Jones</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amy</span> <span property="familyName">MacDougall</span>, <span property="honorificSuffix">B.S.N.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kristen</span> <span property="familyName">Jaworski</span>, <span property="honorificSuffix">M.S.N., F.N.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Noble</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marla</span> <span property="familyName">Curran</span>, <span property="honorificSuffix">Dr.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Klaudia</span> <span property="familyName">Kuranda</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Federico</span> <span property="familyName">Mingozzi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tiffany</span> <span property="familyName">Chang</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kathleen Z.</span> <span property="familyName">Reape</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xavier M.</span> <span property="familyName">Anguela</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Katherine A.</span> <span property="familyName">High</span>, <span property="honorificSuffix">M.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania (L.A.G., B.J.S.-J.), the Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Childrenâs Hospital of Philadelphia (L.A.G., B.J.S.-J.), and Spark Therapeutics (P.E.M., A.M., K.J., R.N., M.C., K.K., F.M., T.C., K.Z.R., X.M.A., K.A.H.), Philadelphia, the Department of Medicine, Division of Hematology and Oncology, Penn State Health Milton S. Hershey Medical Center, Hershey (M.E.E.), and the Department of Medicine, University of Pittsburgh, Pittsburgh (M.V.R.) â all in Pennsylvania; the Department of Pediatrics, Division of Hematology, Mississippi Center for Advanced Medicine, Madison (S.K.S.); the Department of Pediatrics, Harvard Medical School, and the Division of Hematology and Oncology, Boston Childrenâs Hospital â both in Boston (S.E.C.); the Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, University of Sydney â both in Camperdown, NSW, Australia (J.E.J.R.); the Hemophilia Center, Oregon Health and Science University, Portland (M.R.); and the American Thrombosis and Hemostasis Network, Rochester, NY (M.R.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. George can be contacted at <a href="mailto:georgel@email.chop.edu">georgel@email.chop.edu</a> or at the Perelman School of Medicine at the University of Pennsylvania, Childrenâs Hospital of Philadelphia, Colket Translational Research Bldg., Rm. 5016, 3501 Civic Center Blvd., Philadelphia, PA 19104.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">167</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2104205" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="1aefc3dd-014a-9eb6-79c1-de21e9dae729"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447" style="display:inline-block;">
                <img alt="Article has an altmetric score of 543" src="https://badges.altmetric.com/?size=320&amp;score=543&amp;types=mabrtttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_1aefc3dd-014a-9eb6-79c1-de21e9dae729" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447&amp;tab=news">
          Picked up by <b>60</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447&amp;tab=twitter">
          Posted by <b>129</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447&amp;tab=patents">
          Referenced in <b>5</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=117098447&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>191</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6a8d8a645f2b4-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2104205"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2104205%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="167" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Stine Sofie Frank Lende, </li><li class="list-inline-item cited-by__entry__author">Frederik Holm Rothemejer, </li><li class="list-inline-item cited-by__entry__author">Malthe Andreas, </li><li class="list-inline-item cited-by__entry__author">Maria Lange Pedersen, </li><li class="list-inline-item cited-by__entry__author">Laura Traberg-Nyborg, </li><li class="list-inline-item cited-by__entry__author">Emma Falling Iversen, </li><li class="list-inline-item cited-by__entry__author">Anna Karina Juhl, </li><li class="list-inline-item cited-by__entry__author">Ole Schmeltz SÃ¸gaard, </li><li class="list-inline-item cited-by__entry__author">Mariane HÃ¸gsbjerg Schleimann, </li><li class="list-inline-item cited-by__entry__author">Martin Tolstrup, </li></ul><span class="cited-by__entry__title">Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis, </span><span class="cited-by__entry__series-title">Virology, </span><span class="cited-by__entry__volume"><strong>610</strong>, </span><span class="cited-by__entry__page-range">(110573), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.virol.2025.110573" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.virol.2025.110573</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.virol.2025.110573" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Barry J. Byrne, </li><li class="list-inline-item cited-by__entry__author">Kevin M. Flanigan, </li><li class="list-inline-item cited-by__entry__author">Susan E. Matesanz, </li><li class="list-inline-item cited-by__entry__author">Richard S. Finkel, </li><li class="list-inline-item cited-by__entry__author">Megan A. Waldrop, </li><li class="list-inline-item cited-by__entry__author">Eleonora S. D'Ambrosio, </li><li class="list-inline-item cited-by__entry__author">Nicholas E. Johnson, </li><li class="list-inline-item cited-by__entry__author">Barbara K. Smith, </li><li class="list-inline-item cited-by__entry__author">Carsten BÃ¶nnemann, </li><li class="list-inline-item cited-by__entry__author">Sean Carrig, </li><li class="list-inline-item cited-by__entry__author">Joseph W. Rossano, </li><li class="list-inline-item cited-by__entry__author">Barry Greenberg, </li><li class="list-inline-item cited-by__entry__author">Laura Lalaguna, </li><li class="list-inline-item cited-by__entry__author">Enrique Lara-Pezzi, </li><li class="list-inline-item cited-by__entry__author">Sub Subramony, </li><li class="list-inline-item cited-by__entry__author">Manuela Corti, </li><li class="list-inline-item cited-by__entry__author">Claudia Mercado-Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Carmen Leon-Astudillo, </li><li class="list-inline-item cited-by__entry__author">Rebecca Ahrens-Nicklas, </li><li class="list-inline-item cited-by__entry__author">Diana Bharucha-Goebel, </li><li class="list-inline-item cited-by__entry__author">Guangping Gao, </li><li class="list-inline-item cited-by__entry__author">Dominic J. Gessler, </li><li class="list-inline-item cited-by__entry__author">Wuh-Liang Hwu, </li><li class="list-inline-item cited-by__entry__author">Yin-Hsiu Chien, </li><li class="list-inline-item cited-by__entry__author">Ni-Chung Lee, </li><li class="list-inline-item cited-by__entry__author">Sanford L. Boye, </li><li class="list-inline-item cited-by__entry__author">Shannon E. Boye, </li><li class="list-inline-item cited-by__entry__author">Lindsey A. George, </li></ul><span class="cited-by__entry__title">Current clinical applications of AAV-mediated gene therapy, </span><span class="cited-by__entry__series-title">Molecular Therapy, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(2479-2516), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ymthe.2025.04.045" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ymthe.2025.04.045</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ymthe.2025.04.045" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Courtney D. Thornburg, </li><li class="list-inline-item cited-by__entry__author">Steve W. Pipe, </li><li class="list-inline-item cited-by__entry__author">Alessio Cantore, </li><li class="list-inline-item cited-by__entry__author">Carmen Unzu, </li><li class="list-inline-item cited-by__entry__author">Micheala Jones, </li><li class="list-inline-item cited-by__entry__author">Wolfgang A. Miesbach, </li></ul><span class="cited-by__entry__title">Clinical perspective: Advancing hemophilia treatment through gene therapy approaches, </span><span class="cited-by__entry__series-title">Molecular Therapy, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(2350-2362), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ymthe.2025.04.023" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ymthe.2025.04.023</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ymthe.2025.04.023" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Aneesh Rajwade, </li><li class="list-inline-item cited-by__entry__author">Shufang Liu, </li><li class="list-inline-item cited-by__entry__author">Mokshada Kumar, </li><li class="list-inline-item cited-by__entry__author">Avanobe Ghobrial, </li><li class="list-inline-item cited-by__entry__author">Sara Hahn, </li><li class="list-inline-item cited-by__entry__author">Dhaval K. Shah, </li></ul><span class="cited-by__entry__title">Investigation of dose-exposure-response relationship for adeno-associated virusâmediated delivery of antibody genes, </span><span class="cited-by__entry__series-title">The Journal of Pharmacology and Experimental Therapeutics, </span><span class="cited-by__entry__volume"><strong>392</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(103601), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jpet.2025.103601" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jpet.2025.103601</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jpet.2025.103601" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wuxia Yang, </li><li class="list-inline-item cited-by__entry__author">Aidi Wang, </li><li class="list-inline-item cited-by__entry__author">Baoshan Liu, </li></ul><span class="cited-by__entry__title">Adeno-associated virus gene therapy for hemophilia: an update meta-analysis and systematic review, </span><span class="cited-by__entry__series-title">Frontiers in Medicine, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fmed.2025.1580264" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fmed.2025.1580264</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fmed.2025.1580264" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yangxin Fang, </li><li class="list-inline-item cited-by__entry__author">Lin Chen, </li><li class="list-inline-item cited-by__entry__author">Yin Yuan, </li><li class="list-inline-item cited-by__entry__author">Sining Zhou, </li><li class="list-inline-item cited-by__entry__author">Jiamin Fu, </li><li class="list-inline-item cited-by__entry__author">Qi Zhang, </li><li class="list-inline-item cited-by__entry__author">Ning Zhang, </li><li class="list-inline-item cited-by__entry__author">Yuqi Huang, </li><li class="list-inline-item cited-by__entry__author">Yifei Li, </li><li class="list-inline-item cited-by__entry__author">Li Yuan, </li><li class="list-inline-item cited-by__entry__author">Lijun Chen, </li><li class="list-inline-item cited-by__entry__author">Charlie Xiang, </li></ul><span class="cited-by__entry__title">Human menstrual blood-derived stem cells secreted ECM1 directly interacts with LRP1Î± to ameliorate hepatic fibrosis through FoxO1 and mTOR signaling pathway, </span><span class="cited-by__entry__series-title">Stem Cell Research &amp; Therapy, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13287-025-04351-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13287-025-04351-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13287-025-04351-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Roland W. Herzog, </li><li class="list-inline-item cited-by__entry__author">Radoslaw Kaczmarek, </li><li class="list-inline-item cited-by__entry__author">Katherine A. High, </li></ul><span class="cited-by__entry__title">Gene therapy for hemophilia&nbsp;â From basic science to first approvals of âone-and-doneâ therapies, </span><span class="cited-by__entry__series-title">Molecular Therapy, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(2015-2034), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ymthe.2025.03.043" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ymthe.2025.03.043</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ymthe.2025.03.043" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Francesco Puzzo, </li><li class="list-inline-item cited-by__entry__author">Mark A. Kay, </li></ul><span class="cited-by__entry__title">The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy, </span><span class="cited-by__entry__series-title">Molecular Therapy, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1966-1987), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ymthe.2025.03.041" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ymthe.2025.03.041</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ymthe.2025.03.041" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Radoslaw Kaczmarek, </li><li class="list-inline-item cited-by__entry__author">Benjamin J. Samelson-Jones, </li></ul><span class="cited-by__entry__title">The timely reporting of clinical trial results answers 1 unknown for hemophilia gene therapy: no benefit of prophylactic immunosuppression, </span><span class="cited-by__entry__series-title">Journal of Thrombosis and Haemostasis, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1477-1479), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jtha.2025.02.005" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jtha.2025.02.005</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jtha.2025.02.005" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lu Zhang, </li><li class="list-inline-item cited-by__entry__author">Jinxia Guo, </li><li class="list-inline-item cited-by__entry__author">Shufang Wei, </li><li class="list-inline-item cited-by__entry__author">Jiajia Li, </li><li class="list-inline-item cited-by__entry__author">Yincong Dou, </li><li class="list-inline-item cited-by__entry__author">Tianming Cheng, </li><li class="list-inline-item cited-by__entry__author">Yinghui Ge, </li><li class="list-inline-item cited-by__entry__author">Tuo Zhang, </li></ul><span class="cited-by__entry__title">The prediction of haemophilic arthropathy progression based on MRI findings and clinical characteristics, </span><span class="cited-by__entry__series-title">Orphanet Journal of Rare Diseases, </span><span class="cited-by__entry__volume"><strong>20</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13023-025-03716-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13023-025-03716-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13023-025-03716-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2104205%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2104205" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2104205" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2104205.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f0.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/c0d52942-def0-41fa-9959-9cbaa81257e1/assets/images/large/nejmoa2104205_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f1.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/a328bc7e-d37f-4c93-bb5b-8f166c22c7a7/assets/images/large/nejmoa2104205_f1.jpg" height="1520" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Factor VIII Activity after Infusion of SPK-8011 in 18 Participants.</div><div class="notes"><div role="doc-footnote">The SPK-8011 vector was administered in four doses: 5Ã10<sup>11</sup> vector genomes (vg) per kilogram of body weight, 1Ã10<sup>12</sup> vg per kilogram, 1.5Ã10<sup>12</sup> vg per kilogram, and 2Ã10<sup>12</sup> vg per kilogram. On the y axis, factor VIII activity is shown on a log scale. The number to the right of each line is the participant number. Factor VIII activity was determined with the use of a one-stage factor VIII assay. The gray shaded area indicates the range of factor VIII activity in mild hemophilia A. Participants 5 and 12 lost transgene expression.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f2.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/24e3a46a-2c39-44fa-9967-87ffd6354507/assets/images/large/nejmoa2104205_f2.jpg" height="3438" width="2630" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Preliminary Efficacy of SPK-8011.</div><div class="notes"><div role="doc-footnote">Panel A shows the annualized rate of bleeding events before and after vector infusion. Panel B shows the annualized number of exogenous factor VIII infusions before and after vector infusion. Participants 5 and 12 lost all transgene expression within 1 year after vector administration, and the data shown are for the period of transgene expression only. Panel C shows the percentage of participants with no bleeding events after SPK-8011 administration. The number of participants who completed each follow-up interval is indicated below the x-axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f3.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/fb1ad4aa-728b-42da-ba6a-fa2d82ddc352/assets/images/large/nejmoa2104205_f3.jpg" height="3438" width="2126" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Correlation between Factor VIII Activity and the Rate of Spontaneous Bleeding Events.</div><div class="notes"><div role="doc-footnote">Panel A shows the factor VIII activity relative to the annualized rate of spontaneous bleeding among Participants 1 through 18. Factor VIII activity was determined with the use of a one-stage factor VIII assay. A Bayesian negative binomial regression analysis with noninformative priors was used to analyze the relationship between the annualized rate of spontaneous bleeding after vector administration and the proportion of time participants had factor VIII activity that was greater than 10% of the normal value. The blue curve indicates the regression line, and the shaded area the 95% credible interval. Each X denotes one participant, and the participant numbers are shown. Data shown for Participants 5 and 12 are based on observations before the loss of transgene expression. Panel B shows the posterior density of the mean annualized rate of spontaneous bleeding among participants with factor VIII activity of more than 10% of the normal value at least half the time; among these participants, there was a 99% probability of an annualized rate of spontaneous bleeding of less than 1 event. The gray vertical line indicates an annualized rate of spontaneous bleeding of 1 event.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2104205/asset/c410c551-80b8-4f3f-9c4b-57c0e0652d5a/assets/images/large/nejmoa2104205_t1.jpg" height="3438" width="2595" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxr-borders" colspan="18"><span>SPK-8011 Dose</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>5Ã10<sup>11</sup> vg/kg</span></th><th class="xxxx-borders" colspan="3"><span>1Ã10<sup>12</sup> vg/kg</span></th><th class="xxxx-borders" colspan="9"><span>2Ã10<sup>12</sup> vg/kg</span></th><th class="xxxr-borders" colspan="4"><span>1.5Ã10<sup>12</sup> vg/kg</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="18"><span>participant number</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">1</th><th class="xxxx-borders">2</th><th class="xxxx-borders">3</th><th class="xxxx-borders">4</th><th class="xxxx-borders">6</th><th class="xxxx-borders">5</th><th class="xxxx-borders">7</th><th class="xxxx-borders">8</th><th class="xxxx-borders">9</th><th class="xxxx-borders">10</th><th class="xxxx-borders">11</th><th class="xxxx-borders">12</th><th class="xxxx-borders">13</th><th class="xxxx-borders">14</th><th class="xxxx-borders">15</th><th class="xxxx-borders">16</th><th class="xxxx-borders">17</th><th class="xxxr-borders">18</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>At baseline</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Age â yr</td><td class="xxxx-borders">52</td><td class="xxxx-borders">45</td><td class="xxxx-borders">34</td><td class="xxxx-borders">34</td><td class="xxxx-borders">48</td><td class="xxxx-borders">27</td><td class="xxxx-borders">28</td><td class="xxxx-borders">18</td><td class="xxxx-borders">34</td><td class="xxxx-borders">39</td><td class="xxxx-borders">21</td><td class="xxxx-borders">21</td><td class="xxxx-borders">18</td><td class="xxxx-borders">34</td><td class="xxxx-borders">39</td><td class="xxxx-borders">40</td><td class="xxxx-borders">20</td><td class="xxxr-borders">39</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Weight â kg</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">82</td><td class="xxxx-borders shading">89</td><td class="xxxx-borders shading">60</td><td class="xxxx-borders shading">79</td><td class="xxxx-borders shading">93</td><td class="xxxx-borders shading">72</td><td class="xxxx-borders shading">78</td><td class="xxxx-borders shading">78</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">69</td><td class="xxxx-borders shading">121</td><td class="xxxx-borders shading">60</td><td class="xxxx-borders shading">115</td><td class="xxxx-borders shading">60</td><td class="xxxr-borders shading">95</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">BMI<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">22</td><td class="xxxx-borders">29</td><td class="xxxx-borders">25</td><td class="xxxx-borders">26</td><td class="xxxx-borders">28</td><td class="xxxx-borders">19</td><td class="xxxx-borders">24</td><td class="xxxx-borders">29</td><td class="xxxx-borders">22</td><td class="xxxx-borders">26</td><td class="xxxx-borders">24</td><td class="xxxx-borders">24</td><td class="xxxx-borders">28</td><td class="xxxx-borders">30</td><td class="xxxx-borders">21</td><td class="xxxx-borders">32</td><td class="xxxx-borders">22</td><td class="xxxr-borders">30</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Factor VIII activity â % normal value</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">1â2</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxx-borders shading">&lt;1</td><td class="xxxr-borders shading">&lt;1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Genotype</td><td class="xxxx-borders">Ser1070x</td><td class="xxxx-borders">Arg218<br>2His</td><td class="xxxx-borders">Arg81<br>4x</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Arg301<br>Leu</td><td class="xxxx-borders">Intr 1<br>inv</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Arg21<br>66X</td><td class="xxxx-borders">His855<br>Leufs*2</td><td class="xxxx-borders">Intr 22<br>inv</td><td class="xxxx-borders">Ex<br>20â22<br>del</td><td class="xxxx-borders">Ph2294<br>Serfs*90</td><td class="xxxx-borders">Val402<br>Tyrfs*</td><td class="xxxx-borders">Arg218<br>2His</td><td class="xxxx-borders">Glu98<br>Lys</td><td class="xxxx-borders">Intr 22<br> inv</td><td class="xxxr-borders">Tyr1834<br>Asp</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Cross-reacting material status<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxr-borders shading">+</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Use of prophylaxis</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">No</td><td class="xxxx-borders">Yes</td><td class="xxxx-borders">Yes</td><td class="xxxr-borders">Yes</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Treatment type</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">pdFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL- rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxx-borders shading">EHL-rFVIII</td><td class="xxxr-borders shading">EHL-rFVIII</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Factor VIII dose â IU/kg</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">65 twice weekly</td><td class="xxxx-borders">30 twice weekly</td><td class="xxxx-borders">50 twice weekly and 25 weekly</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">50 every other day</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">25 every other day</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">20 twice weekly</td><td class="xxxx-borders">45 every 4 days</td><td class="xxxx-borders">60 twice weekly</td><td class="xxxx-borders">60 weekly</td><td class="xxxx-borders">40 twice weekly</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">50 weekly</td><td class="xxxx-borders">55 twice weekly</td><td class="xxxr-borders">50 every 5 days</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Arthropathic joints â no.</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">2</td></tr><tr data-type="row"><td class="xxlx-borders">Infection history<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">HCV</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxr-borders shading">+</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">HBV</td><td class="xxxx-borders">â</td><td class="xxxx-borders">+</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">+</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">+</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxx-borders">â</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">HIV</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">+</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">â</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Liver fibrosis (test)<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">F1<br> (TE)</td><td class="xxxx-borders">F2<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F1âF2<br> (SMF)</td><td class="xxxx-borders">F1<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (TE)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0âF1<br> (SMF)</td><td class="xxxx-borders">F0<br> (APRI)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0<br> (APRI)</td><td class="xxxx-borders">F1<br> (TE)</td><td class="xxxx-borders">F0<br> (SMF)</td><td class="xxxx-borders">F0âF1<br> (SMF)</td><td class="xxxr-borders">F0<br> (SMF)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><b>After gene</b> <b>transfer</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders">Immune suppression</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Use</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">No</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxx-borders shading">Yes</td><td class="xxxr-borders shading">Yes</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Wk</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">8</td><td class="xxxx-borders">6</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">13</td><td class="xxxx-borders">5</td><td class="xxxx-borders">18</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">8</td><td class="xxxx-borders">14</td><td class="xxxx-borders">16</td><td class="xxxx-borders">44<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">32<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">66<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">52<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxr-borders">3</td></tr><tr data-type="row"><td class="xxlx-borders shading">Factor VIII activity â IU/dl<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Peak</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">OSA</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">25</td><td class="xxxx-borders shading">16</td><td class="xxxx-borders shading">63</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">23</td><td class="xxxx-borders shading">70</td><td class="xxxx-borders shading">22</td><td class="xxxx-borders shading">194</td><td class="xxxx-borders shading">209</td><td class="xxxx-borders shading">43</td><td class="xxxx-borders shading">48</td><td class="xxxx-borders shading">55</td><td class="xxxr-borders shading">94</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">CSA</td><td class="xxxx-borders">10</td><td class="xxxx-borders">8</td><td class="xxxx-borders">5</td><td class="xxxx-borders">15</td><td class="xxxx-borders">14</td><td class="xxxx-borders">16</td><td class="xxxx-borders">37</td><td class="xxxx-borders">20</td><td class="xxxx-borders">8</td><td class="xxxx-borders">15</td><td class="xxxx-borders">46</td><td class="xxxx-borders">16</td><td class="xxxx-borders">117</td><td class="xxxx-borders">117</td><td class="xxxx-borders">29</td><td class="xxxx-borders">29</td><td class="xxxx-borders">38</td><td class="xxxr-borders">70</td></tr><tr data-type="row"><td class="xxlx-borders full shading">Mean, after 52 wk</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">OSA</td><td class="xxxx-borders">11</td><td class="xxxx-borders">8</td><td class="xxxx-borders">5</td><td class="xxxx-borders">8</td><td class="xxxx-borders">22</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">25</td><td class="xxxx-borders">3</td><td class="xxxx-borders">8</td><td class="xxxx-borders">16</td><td class="xxxx-borders">16</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">6</td><td class="xxxx-borders">17</td><td class="xxxx-borders">12</td><td class="xxxx-borders">4</td><td class="xxxx-borders">5</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CSA</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">11</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">11</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders full" data-xml-align="left">Maximum AFP level â ng/ml<a href="#core-t1fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders">9.0</td><td class="xxxx-borders">3.5</td><td class="xxxx-borders">2.2</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">6.6</td><td class="xxxx-borders">1.8</td><td class="xxxx-borders">4.1</td><td class="xxxx-borders">2.5</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">2.7</td><td class="xxxx-borders">1.6</td><td class="xxxx-borders">2.3</td><td class="xxxx-borders">1.8</td><td class="xxxx-borders">3.7</td><td class="xxxx-borders">3.2</td><td class="xxxx-borders">1.7</td><td class="xxxx-borders">2.6</td><td class="xxxr-borders">8.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders full shading" data-xml-align="left">Duration of safety follow-up â mo</td><td class="xbxx-borders shading">50.3</td><td class="xbxx-borders shading">47.8</td><td class="xbxx-borders shading">45.5</td><td class="xbxx-borders shading">44.2</td><td class="xbxx-borders shading">41.1</td><td class="xbxx-borders shading">32.6</td><td class="xbxx-borders shading">40.9</td><td class="xbxx-borders shading">36.8</td><td class="xbxx-borders shading">36.7</td><td class="xbxx-borders shading">36.5</td><td class="xbxx-borders shading">36.1</td><td class="xbxx-borders shading">35.9</td><td class="xbxx-borders shading">31.7</td><td class="xbxx-borders shading">25.4</td><td class="xbxx-borders shading">23.7</td><td class="xbxx-borders shading">20.7</td><td class="xbxx-borders shading">19.8</td><td class="xbxr-borders shading">5.5</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">AFP denotes alpha-fetoprotein, APRI aspartate aminotransferaseâto-platelet ratio index, del deletion, EHL extended half-life, ex exon, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, int intron, inv inversion, NA not applicable, pdFVIII, plasma-derived factor VIII, rFVIII, recombinant factor VIII, SMF serum markers of fibrosis, and TE transient elastography.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Positive results (plus sign) for cross-reacting material indicate that FVIII protein is detectable but dysfunctional at baseline, whereas negative results (minus sign) indicate no detectable FVIII protein at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">A positive HCV, HBV, or HIV status (plus sign) indicates that the participant had serologic findings consistent with a history of infection but a negative viral polymerase-chain-reaction test at enrollment. A minus sign indicates that the participant did not have serologic findings consistent with a history of infection.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Liver fibrosis was assessed on a scale of F0 to F4, with higher stages indicating a greater degree of fibrosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Participants 14 through 17 received immune suppression for an extended time because of the use of glucocorticoid-sparing agents.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">On the one-stage factor VIII assay (OSA) and chromogenic factor VIII assay (CSA), the normal range for factor VIII activity is 50 to 150 IU per deciliter.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">The upper limit of the normal range for AFP is 8.9 ng per milliliter.</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Participants at Baseline and after Gene Transfer.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2104205/asset/4ba1db0c-4505-4009-809e-bb28e5fe9eff/assets/images/large/nejmoa2104205_t2.jpg" height="2092" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>2Ã10<sup>12</sup> vg/kg Cohort<br>(N=9)</span></th><th class="txxx-borders" colspan="2"><span>1.5Ã10<sup>12</sup> vg/kg Cohort<br>(N=4)</span></th><th class="txxr-borders" colspan="2"><span>All Participants<br> (N=18)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of<br> Participants (%)</th><th class="xxxx-borders">No. of<br> Events</th><th class="xxxx-borders">No. of<br> Participants (%)</th><th class="xxxx-borders">No. of<br> Events</th><th class="xxxx-borders">No. of<br> Participants (%)</th><th class="xxxr-borders">No. of<br> Events</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Adverse event related to SPK-8011</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any event</td><td class="xxxx-borders">4 (44)</td><td class="xxxx-borders">12</td><td class="xxxx-borders">4 (100)</td><td class="xxxx-borders">5</td><td class="xxxx-borders">8 (44)</td><td class="xxxr-borders">17</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Elevated alanine aminotransferase level</td><td class="xxxx-borders shading">3 (33)</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">4 (100)</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">7 (39)</td><td class="xxxr-borders shading">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">1 (11)<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Myalgia</td><td class="xxxx-borders shading">1 (11)<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Back pain</td><td class="xxxx-borders">1 (11)<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">1 (11)<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Serious adverse event related to SPK-8011</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any serious adverse event</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Elevated liver aminotransferase level</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Adverse event related to glucocorticoid</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any event</td><td class="xxxx-borders">2 (22)</td><td class="xxxx-borders">7</td><td class="xxxx-borders">2 (50)</td><td class="xxxx-borders">9</td><td class="xxxx-borders">4 (22)</td><td class="xxxr-borders">16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Adrenal insufficiency</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Gastroesophageal reflux</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Osteoporosis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Weight gain</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">2</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">2 (11)</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Generalized edema</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hypomagnesemia</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Muscle spasms</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Acne</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Irritability</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Psychomotor hyperactivity</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (25)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Tremor</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (25)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Insomnia</td><td class="xxxx-borders">1 (11)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (6)</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">1 (11)</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (6)</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Hot flash</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (25)</td><td class="xbxx-borders">1</td><td class="xbxx-borders">1 (6)</td><td class="xbxr-borders">1</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The relationship between the events and SPK-8011 or glucocorticoid was determined by the clinical investigators. Data are from the safety observation period. There were no drug-related adverse events or serious adverse events in two vector-dose cohorts (5Ã10<sup>11</sup> vg per kilogram and 1Ã10<sup>12</sup> vg per kilogram).</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">One participant had an infusion reaction consisting of pyrexia, myalgia, back pain, and vomiting.</div></div></div></figcaption></a><figcaption><div class="caption">Drug-Related Adverse Events and Drug-Related Serious Adverse Events.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104205_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2104205</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Everett LA, Cleuren ACA, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. <em>Blood</em> 2014;123:3697-3705.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-02-554501" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24719406/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342617200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Murine+coagulation+factor+VIII+is+synthesized+in+endothelial+cells.&amp;publication_year=2014&amp;journal=Blood&amp;pages=3697-3705&amp;doi=10.1182%2Fblood-2014-02-554501&amp;pmid=24719406" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. <em>Blood</em> 2014;123:3706-3713.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-02-555151" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24705491/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342617200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+conditional+knockout+mouse+model+reveals+endothelial+cells+as+the+principal+and+possibly+exclusive+source+of+plasma+factor+VIII.&amp;publication_year=2014&amp;journal=Blood&amp;pages=3706-3713&amp;doi=10.1182%2Fblood-2014-02-555151&amp;pmid=24705491" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Mannucci PM, Tuddenham EG. The hemophilias â from royal genes to gene therapy. <em>N Engl J Med</em> 2001;344:1773-1779.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJM200106073442307&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11396445/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000169133600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+hemophilias+%E2%80%94+from+royal+genes+to+gene+therapy.&amp;publication_year=2001&amp;journal=N+Engl+J+Med&amp;pages=1773-1779&amp;doi=10.1056%2FNEJM200106073442307&amp;pmid=11396445" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a low risk of spontaneous joint bleeding. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] phenotype in patients with hemophilia A. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. <em>Haemophilia</em> 2011;17:41-44.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2516.2010.02383.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20825504/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285762900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analysis+of+low+frequency+bleeding+data%3A+the+association+of+joint+bleeds+according+to+baseline+FVIII+activity+levels.&amp;publication_year=2011&amp;journal=Haemophilia&amp;pages=41-44&amp;doi=10.1111%2Fj.1365-2516.2010.02383.x&amp;pmid=20825504" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a low risk of spontaneous joint bleeding. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] VIII assay in persons with hemophilia. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. <em>N Engl J Med</em> 2007;357:535-544.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa067659&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17687129/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248584900004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prophylaxis+versus+episodic+treatment+to+prevent+joint+disease+in+boys+with+severe+hemophilia.&amp;publication_year=2007&amp;journal=N+Engl+J+Med&amp;pages=535-544&amp;doi=10.1056%2FNEJMoa067659&amp;pmid=17687129" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. <em>N Engl J Med</em> 2018;379:811-822.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1803550&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30157389/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443047800005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emicizumab+prophylaxis+in+patients+who+have+hemophilia+A+without+inhibitors.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=811-822&amp;doi=10.1056%2FNEJMoa1803550&amp;pmid=30157389" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] phenotype in patients with hemophilia A. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] prophylaxis in severe hemophilia A. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. <em>N Engl J Med</em> 2017;377:2519-2530.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1708483&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29224506/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000418777700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=AAV5-factor+VIII+gene+transfer+in+severe+hemophilia+A.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2519-2530&amp;doi=10.1056%2FNEJMoa1708483&amp;pmid=29224506" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] data showed that this decrease continued. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] other trials of therapy for hemophilia A, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] gene therapy for hemophilia A. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the 4 years of available follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] with AAV5-hFVIII-SQ), and the promoter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] were similar to those of AAV5-hFVIII-SQ </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. <em>N Engl J Med</em> 2020;382:29-40.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1908490&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31893514/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505606700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiyear+follow-up+of+AAV5-hFVIII-SQ+gene+therapy+for+hemophilia+A.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=29-40&amp;doi=10.1056%2FNEJMoa1908490&amp;pmid=31893514" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] data showed that this decrease continued. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] trials of gene therapy for hemophilia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] gene therapy for hemophilia A. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the 4 years of available follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] with AAV5-hFVIII-SQ), and the promoter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] were similar to those of AAV5-hFVIII-SQ </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] vector administration as that of SPK-8011. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Pasi KJ, Rangarajan S, Mitchell N, et al. A first-in-human four-year follow-up study of durable therapeutic efficacy and safety of AAV gene therapy with valoctocogene roxaparvovec for severe haemophilia A. <em>Haemophilia</em> 2020;26:Suppl 4:151-151. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31859415/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503505000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+first-in-human+four-year+follow-up+study+of+durable+therapeutic+efficacy+and+safety+of+AAV+gene+therapy+with+valoctocogene+roxaparvovec+for+severe+haemophilia+A.&amp;publication_year=2020&amp;journal=Haemophilia&amp;pages=151-151&amp;pmid=31859415" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] data showed that this decrease continued. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the 4 years of available follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] vector administration as that of SPK-8011. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. <em>N Engl J Med</em> 2014;371:1994-2004.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1407309&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25409372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345002900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+safety+and+efficacy+of+factor+IX+gene+therapy+in+hemophilia+B.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1994-2004&amp;doi=10.1056%2FNEJMoa1407309&amp;pmid=25409372" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Nathwani ACRU, Tuddenham E, Chowdary P, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removingâ empty viral particlesâ on safety and efficacy of gene transfer. <em>Blood</em> 2019;132:491-491. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2018-99-118334" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454837601200" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adeno-associated+mediated+gene+transfer+for+hemophilia+B%3A+8+year+follow+up+and+impact+of+removing%E2%80%9D+empty+viral+particles%E2%80%9D+on+safety+and+efficacy+of+gene+transfer.&amp;publication_year=2019&amp;journal=Blood&amp;pages=491-491&amp;doi=10.1182%2Fblood-2018-99-118334" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Nguyen GN, Everett JK, Kafle S, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. <em>Nat Biotechnol</em> 2021;39:47-55.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41587-020-0741-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33199875/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000590031600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+long-term+study+of+AAV+gene+therapy+in+dogs+with+hemophilia+A+identifies+clonal+expansions+of+transduced+liver+cells.&amp;publication_year=2021&amp;journal=Nat+Biotechnol&amp;pages=47-55&amp;doi=10.1038%2Fs41587-020-0741-7&amp;pmid=33199875" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. <em>Nat Med</em> 2007;13:419-422.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm1549" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17369837/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245543900029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CD8%28%2B%29+T-cell+responses+to+adeno-associated+virus+capsid+in+humans.&amp;publication_year=2007&amp;journal=Nat+Med&amp;pages=419-422&amp;doi=10.1038%2Fnm1549&amp;pmid=17369837" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. <em>Nat Med</em> 2006;12:342-347.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm1358" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16474400/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000235802900035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Successful+transduction+of+liver+in+hemophilia+by+AAV-factor+IX+and+limitations+imposed+by+the+host+immune+response.&amp;publication_year=2006&amp;journal=Nat+Med&amp;pages=342-347&amp;doi=10.1038%2Fnm1358&amp;pmid=16474400" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. <em>N Engl J Med</em> 2011;365:2357-2365.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1108046&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22149959/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000298320200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adenovirus-associated+virus+vector-mediated+gene+transfer+in+hemophilia+B.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=2357-2365&amp;doi=10.1056%2FNEJMoa1108046&amp;pmid=22149959" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not all, recipients of AAV gene therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] AAV-mediated gene therapy for hemophilia B </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. <em>N Engl J Med</em> 2017;377:2215-2227.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104205&amp;key=10.1056%2FNEJMoa1708538&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29211678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417201100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hemophilia+B+gene+therapy+with+a+high-specific-activity+factor+IX+variant.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2215-2227&amp;doi=10.1056%2FNEJMoa1708538&amp;pmid=29211678" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not all, recipients of AAV gene therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] peripheral-blood mononuclear cells (PBMCs). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of AAV gene therapy for hemophilia B. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] trials of gene therapy for hemophilia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] AAV-mediated gene therapy for hemophilia B </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. <em>Blood</em> 2021;137:763-774.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004625" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33067633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000617757100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BAX+335+hemophilia+B+gene+therapy+clinical+trial+results%3A+potential+impact+of+CpG+sequences+on+gene+expression.&amp;publication_year=2021&amp;journal=Blood&amp;pages=763-774&amp;doi=10.1182%2Fblood.2019004625&amp;pmid=33067633" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] not all, recipients of AAV gene therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in another trial of AAV gene transfer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] content in the vector cassette, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. <em>Nature</em> 2014;506:382-386.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature12875" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24390344/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000331477800044" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Selection+and+evaluation+of+clinically+relevant+AAV+variants+in+a+xenograft+liver+model.&amp;publication_year=2014&amp;journal=Nature&amp;pages=382-386&amp;doi=10.1038%2Fnature12875&amp;pmid=24390344" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Anguela XM, Shen SH. CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders. U.S. patent application no. 0216408A1. August 3, 2017.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CpG+reduced+factor+VIII+variants%2C+compositions+and+methods+and+uses+for+treatment+of+hemostasis+disorders&amp;publication_year=2017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. <em>J Clin Invest</em> 2015;125:870-880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI79213" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25607839/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348962700040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vector+design+influences+hepatic+genotoxicity+after+adeno-associated+virus+gene+therapy.&amp;publication_year=2015&amp;journal=J+Clin+Invest&amp;pages=870-880&amp;doi=10.1172%2FJCI79213&amp;pmid=25607839" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. <em>Science</em> 2007;317:477-477.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1142658" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17656716/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248339800034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=AAV+vector+integration+sites+in+mouse+hepatocellular+carcinoma.&amp;publication_year=2007&amp;journal=Science&amp;pages=477-477&amp;doi=10.1126%2Fscience.1142658&amp;pmid=17656716" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Konkle BASK, Visweshwar N, Harrington TJ, et al. Updated follow-up of the Alta study, a phase 1/2, open-label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy. <em>Blood</em> 2019;134:Suppl 1:2060-2060. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2019-122143" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577160404018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+follow-up+of+the+Alta+study%2C+a+phase+1%2F2%2C+open-label%2C+adaptive%2C+dose-ranging+study+to+assess+the+safety+and+tolerability+of+SB-525+gene+therapy.&amp;publication_year=2019&amp;journal=Blood&amp;pages=2060-2060&amp;doi=10.1182%2Fblood-2019-122143" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Miesbach WMK, Coppens M, Kampmann P, et al. Stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 4 years following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B. <em>Blood</em> 2019;134:Suppl 1:2059-2059. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2019-122535" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31697809/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577160404017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stable+FIX+expression+and+durable+reductions+in+bleeding+and+factor+IX+consumption+for+up+to+4+years+following+AMT-060+gene+therapy+in+adults+with+severe+or+moderate-severe+hemophilia+B.&amp;publication_year=2019&amp;journal=Blood&amp;pages=2059-2059&amp;doi=10.1182%2Fblood-2019-122535&amp;pmid=31697809" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. <em>J Virol</em> 2005;79:9933-9944.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.79.15.9933-9944.2005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16014954/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230575300055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Packaging+capacity+of+adeno-associated+virus+serotypes%3A+impact+of+larger+genomes+on+infectivity+and+postentry+steps.&amp;publication_year=2005&amp;journal=J+Virol&amp;pages=9933-9944&amp;doi=10.1128%2FJVI.79.15.9933-9944.2005&amp;pmid=16014954" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. <em>Science</em> 2011;334:1081-1086.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1209038" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22116877/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297313900038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+unfolded+protein+response%3A+from+stress+pathway+to+homeostatic+regulation.&amp;publication_year=2011&amp;journal=Science&amp;pages=1081-1086&amp;doi=10.1126%2Fscience.1209038&amp;pmid=22116877" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Malhotra JD, Miao H, Zhang K, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. <em>Proc Natl Acad Sci U S A</em> 2008;105:18525-18530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0809677105" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19011102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261489300087" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antioxidants+reduce+endoplasmic+reticulum+stress+and+improve+protein+secretion.&amp;publication_year=2008&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=18525-18530&amp;doi=10.1073%2Fpnas.0809677105&amp;pmid=19011102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Lange AM, Altynova ES, Nguyen GN, Sabatino DE. Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. <em>Mol Ther Methods Clin Dev</em> 2016;3:16064-16064.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/mtm.2016.64" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27738645/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393455200054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overexpression+of+factor+VIII+after+AAV+delivery+is+transiently+associated+with+cellular+stress+in+hemophilia+A+mice.&amp;publication_year=2016&amp;journal=Mol+Ther+Methods+Clin+Dev&amp;pages=16064-16064&amp;doi=10.1038%2Fmtm.2016.64&amp;pmid=27738645" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Poothong J, Pottekat A, Siirin M, et al. Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. <em>Blood</em> 2020;135:1899-1911.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019002867" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32128578/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535968000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+VIII+exhibits+chaperone-dependent+and+glucose-regulated+reversible+amyloid+formation+in+the+endoplasmic+reticulum.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1899-1911&amp;doi=10.1182%2Fblood.2019002867&amp;pmid=32128578" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Becker S, Simpson JC, Pepperkok R, et al. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. <em>Thromb Haemost</em> 2004;92:23-35.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1160/TH03-06-0360" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15213841/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000222711200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Confocal+microscopy+analysis+of+native%2C+full+length+and+B-domain+deleted+coagulation+factor+VIII+trafficking+in+mammalian+cells.&amp;publication_year=2004&amp;journal=Thromb+Haemost&amp;pages=23-35&amp;doi=10.1160%2FTH03-06-0360&amp;pmid=15213841" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Brown HC, Gangadharan B, Doering CB. Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response. <em>J Biol Chem</em> 2011;286:24451-24457.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1074/jbc.M111.238758" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21606503/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292294900085" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Enhanced+biosynthesis+of+coagulation+factor+VIII+through+diminished+engagement+of+the+unfolded+protein+response.&amp;publication_year=2011&amp;journal=J+Biol+Chem&amp;pages=24451-24457&amp;doi=10.1074%2Fjbc.M111.238758&amp;pmid=21606503" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Zolotukhin I, Markusic DM, Palaschak B, Hoffman BE, Srikanthan MA, Herzog RW. Potential for cellular stress response to hepatic factor VIII expression from AAV vector. <em>Mol Ther Methods Clin Dev</em> 2016;3:16063-16063.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/mtm.2016.63" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27738644/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393455200053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Potential+for+cellular+stress+response+to+hepatic+factor+VIII+expression+from+AAV+vector.&amp;publication_year=2016&amp;journal=Mol+Ther+Methods+Clin+Dev&amp;pages=16063-16063&amp;doi=10.1038%2Fmtm.2016.63&amp;pmid=27738644" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Chan YK, Wang SK, Chu CJ, et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. <em>Sci Transl Med</em> 2021;13:eabd3438-eabd3438.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.abd3438" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33568518/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000617688400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Engineering+adeno-associated+viral+vectors+to+evade+innate+immune+and+inflammatory+responses.&amp;publication_year=2021&amp;journal=Sci+Transl+Med&amp;pages=eabd3438-eabd3438&amp;doi=10.1126%2Fscitranslmed.abd3438&amp;pmid=33568518" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Samelson-Jones BJ, Arruda VR. Protein-engineered coagulation factors for hemophilia gene therapy. <em>Mol Ther Methods Clin Dev</em> 2018;12:184-201.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.omtm.2018.12.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30705923/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000461055600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Protein-engineered+coagulation+factors+for+hemophilia+gene+therapy.&amp;publication_year=2018&amp;journal=Mol+Ther+Methods+Clin+Dev&amp;pages=184-201&amp;doi=10.1016%2Fj.omtm.2018.12.007&amp;pmid=30705923" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Simioni P, Cagnin S, Sartorello F, et al. Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. <em>Blood</em> 2021;137:2383-2393.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2020008168" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33275657/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000646140000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Partial+F8+gene+duplication+%28factor+VIII+Padua%29+associated+with+high+factor+VIII+levels+and+familial+thrombophilia.&amp;publication_year=2021&amp;journal=Blood&amp;pages=2383-2393&amp;doi=10.1182%2Fblood.2020008168&amp;pmid=33275657" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Wilhelm AR, Parsons NA, Samelson-Jones BJ, et al. Activated protein C has a regulatory role in factor VIII function. <em>Blood</em> 2021;137:2532-2543.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2020007562" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33512448/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000648518900014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Activated+protein+C+has+a+regulatory+role+in+factor+VIII+function.&amp;publication_year=2021&amp;journal=Blood&amp;pages=2532-2543&amp;doi=10.1182%2Fblood.2020007562&amp;pmid=33512448" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> North Conway, New Hampshire</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885462/family-medicine-or-internal-medicine-physician-memorial-hospital-north-conway-nh/?query=fjwp&amp;rid=1000">Family Medicine or Internal Medicine Physician - Memorial Hospital North Conway, NH</a></div></div><div class="nejm-widget_item"><div><span> New Jersey</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889685/seeking-general-gastroenterologist-to-join-a-thriving-single-specialty-hospital-affiliated-practice/?query=fjwp&amp;rid=395016">Seeking General Gastroenterologist to Join a Thriving Single Specialty Hospital Affiliated Practice</a></div></div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877469/pediatric-hospitalist-position-in-southeastern-ny-day-and-night-shifts/?query=fjwf&amp;rid=475926">Pediatric Hospitalist Position in Southeastern NY | Day &amp; Night Shifts</a></div></div><div class="nejm-widget_item"><div><span> Texarkana, Texas</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890330/anesthesiologist-big-system-1-group-h1b/?query=fjwf&amp;rid=346908">Anesthesiologist - Big System, #1 group, H1B</a></div></div><div class="nejm-widget_item"><div><span> Pennsylvania</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883640/pennsylvania-openings-1-malignant-hem-2-solid-tumor-oncology-300k-sign-on/?query=fjwf&amp;rid=5263">Pennsylvania Openings: 1) Malignant Hem + 2) Solid Tumor Oncology | 300K Sign-On</a></div></div><div class="nejm-widget_item"><div><span> Akron, Ohio</span></div><div><span>Palliative Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880208/palliative-medicine-staff-physician-akron-ohio/?query=fjwf&amp;rid=2201">Palliative Medicine Staff Physician - Akron, Ohio</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2104205&amp;pubId=41290460&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6a8d8a645f2b4-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6a8d8a645f2b4-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6a8d8a645f2b4-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$405663262$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$405663262$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$405663262$--></div></div><div class="mlt-body"><!--?lit$405663262$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$405663262$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$405663262$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$405663262$-->Feb 23, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211075?query=recirc_Semantic" target="_self">Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A</a></div><div class="mlt-article-authors"><!--?lit$405663262$-->J. Mahlangu and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$405663262$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$405663262$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$405663262$-->Mar 17, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2113708?query=recirc_Semantic" target="_self">Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A</a></div><div class="mlt-article-authors"><!--?lit$405663262$-->M.C. Ozelo and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$405663262$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$405663262$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$405663262$-->Jul 18, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2313795?query=recirc_Semantic" target="_self">Science behind the Study: Bioengineered Factor VIII â More Innovation for Hemophilia A</a></div><div class="mlt-article-authors"><!--?lit$405663262$-->P. Chowdary</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$405663262$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$405663262$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$405663262$-->Jan 30, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2410597?query=recirc_Semantic" target="_self">Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A</a></div><div class="mlt-article-authors"><!--?lit$405663262$-->A. Srivastava and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$405663262$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$405663262$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$405663262$-->Sep 10, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2002699?query=recirc_Semantic" target="_self">BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A</a></div><div class="mlt-article-authors"><!--?lit$405663262$-->B.A. Konkle and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2104205?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2104205" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2104205.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2104205"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2103784" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Early Convalescent Plasma for High-Risk Outpatients with Covid-19</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2109409" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Parathyroid Hormone Resistance and Autoantibodies to the PTH1 Receptor</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f0.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/c0d52942-def0-41fa-9959-9cbaa81257e1/assets/images/large/nejmoa2104205_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f1.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/a328bc7e-d37f-4c93-bb5b-8f166c22c7a7/assets/images/large/nejmoa2104205_f1.jpg" height="1520" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Factor VIII Activity after Infusion of SPK-8011 in 18 Participants.</div><div class="notes"><div role="doc-footnote">The SPK-8011 vector was administered in four doses: 5Ã10<sup>11</sup> vector genomes (vg) per kilogram of body weight, 1Ã10<sup>12</sup> vg per kilogram, 1.5Ã10<sup>12</sup> vg per kilogram, and 2Ã10<sup>12</sup> vg per kilogram. On the y axis, factor VIII activity is shown on a log scale. The number to the right of each line is the participant number. Factor VIII activity was determined with the use of a one-stage factor VIII assay. The gray shaded area indicates the range of factor VIII activity in mild hemophilia A. Participants 5 and 12 lost transgene expression.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f2.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/24e3a46a-2c39-44fa-9967-87ffd6354507/assets/images/large/nejmoa2104205_f2.jpg" height="3438" width="2630" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Preliminary Efficacy of SPK-8011.</div><div class="notes"><div role="doc-footnote">Panel A shows the annualized rate of bleeding events before and after vector infusion. Panel B shows the annualized number of exogenous factor VIII infusions before and after vector infusion. Participants 5 and 12 lost all transgene expression within 1 year after vector administration, and the data shown are for the period of transgene expression only. Panel C shows the percentage of participants with no bleeding events after SPK-8011 administration. The number of participants who completed each follow-up interval is indicated below the x-axis.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104205_f3.jpg"><img src="/cms/10.1056/NEJMoa2104205/asset/fb1ad4aa-728b-42da-ba6a-fa2d82ddc352/assets/images/large/nejmoa2104205_f3.jpg" height="3438" width="2126" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Correlation between Factor VIII Activity and the Rate of Spontaneous Bleeding Events.</div><div class="notes"><div role="doc-footnote">Panel A shows the factor VIII activity relative to the annualized rate of spontaneous bleeding among Participants 1 through 18. Factor VIII activity was determined with the use of a one-stage factor VIII assay. A Bayesian negative binomial regression analysis with noninformative priors was used to analyze the relationship between the annualized rate of spontaneous bleeding after vector administration and the proportion of time participants had factor VIII activity that was greater than 10% of the normal value. The blue curve indicates the regression line, and the shaded area the 95% credible interval. Each X denotes one participant, and the participant numbers are shown. Data shown for Participants 5 and 12 are based on observations before the loss of transgene expression. Panel B shows the posterior density of the mean annualized rate of spontaneous bleeding among participants with factor VIII activity of more than 10% of the normal value at least half the time; among these participants, there was a 99% probability of an annualized rate of spontaneous bleeding of less than 1 event. The gray vertical line indicates an annualized rate of spontaneous bleeding of 1 event.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Participants at Baseline and after Gene Transfer.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Drug-Related Adverse Events and Drug-Related Serious Adverse Events.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/21" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 21</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 18, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2103784" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Early Convalescent Plasma for High-Risk Outpatients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">F.K. Korley and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 18, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2107934" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A. Gupta and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 18, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2106596" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">B. Gentner and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2104205%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2104205&amp;pubId=41290460&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2104205%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2104205&amp;pubId=41290460&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id006696107908158222" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6a8d8a645f2b4-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6a8d8a645f2b4-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6a8d8a645f2b4-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6a8d8a645f2b4-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6a8d8a645f2b4-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6a8d8a645f2b4-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6a8d8a645f2b4-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6a8d8a645f2b4-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6a8d8a645f2b4-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6a8d8a645f2b4-SJC"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6a8d89f1ff2b4',t:'MTc0OTUzNTM0My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6a8d89f1ff2b4&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><dtt-zrowevymauev></dtt-zrowevymauev><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2104205?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-transactionid="2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" id="captureIFrame_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" target="captureIFrame_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="capture_screen"><input id="capture_signIn_js_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="js_version"><input id="capture_signIn_transactionId_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" type="hidden" class="capture_transactionId_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="capture_transactionId"><input id="capture_signIn_form_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="form"><input id="capture_signIn_flow_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="flow"><input id="capture_signIn_client_id_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="client_id"><input id="capture_signIn_redirect_uri_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="redirect_uri"><input id="capture_signIn_response_type_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="response_type"><input id="capture_signIn_flow_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="flow_version"><input id="capture_signIn_settings_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="settings_version"><input id="capture_signIn_locale_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="locale"><input id="capture_signIn_recaptcha_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_2pm7a0hxudrkluaa8kdv2ywc4ogjkct51f0gtgzv" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>